inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading tmo measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap otherassetsnoncurrentus gaap otherliabilitiescurrentus gaap otherliabilitiesnoncurrentus gaap sellinggeneralandadministrativeexpenseus gaap otherassetscurrentus gaap otherassetsnoncurrenttmo gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap customerrelationshipsmembertmo brammerbiomemberus gaap gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap brammerbiomemberus gaap gaap gaap gaap gaap gaap gaap customerrelationshipsmembertmo advancedbioprocessingbusinessmemberus gaap gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap tradenamesmembertmo gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap gaap gaap patheonn patheonn patheonn gaap gaap patheonn memberus gaap gaap customerrelationshipsmemberus gaap gaap gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap patheonn memberus gaap gaap tradenamesmemberus gaap gaap gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap gaap gaap gaap patheonn memberus gaap patheonn membertmo patheonn memberus gaap patheonn membertmo patheonn memberus gaap anatomicalpathologybusinessmemberus gaap anatomicalpathologybusinessmemberus gaap anatomicalpathologybusinessmemberus gaap anatomicalpathologybusinessmemberus gaap anatomicalpathologybusinessmemberus gaap lifesciencessolutionsmemberus gaap lifesciencessolutionsmemberus gaap lifesciencessolutionsmemberus gaap analyticalinstrumentsmemberus gaap analyticalinstrumentsmemberus gaap analyticalinstrumentsmemberus gaap specialtydiagnosticsmemberus gaap specialtydiagnosticsmemberus gaap specialtydiagnosticsmemberus gaap laboratoryproductsandservicesmemberus gaap laboratoryproductsandservicesmemberus gaap laboratoryproductsandservicesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap minimummemberus gaap maximummemberus gaap usequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmembercountry minimummemberus gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap maximummemberus gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap minimummemberus gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap maximummemberus gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap minimummemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap maximummemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap multiassetfundsmembersrt minimummemberus gaap pensionplansdefinedbenefitmemberus gaap maximummembertmo multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap minimummemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembertmo maximummemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembertmo minimummemberus gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap maximummemberus gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap usequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap hedgefundsmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembertmo gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembertmo insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap usequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry usequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap equityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap hedgefundsmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembertmo gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembertmo insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap gaap commercialpapermembertmo gaap commercialpapermembertmo gaap gaap gaap gaap seniornotesmemberus gaap interestrateswapmembertmo gaap gaap gaap gaap gaap gaap financialguaranteemembertmo minimummembertmo maximummembertmo incometaxesonnetinvestmenthedgemembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap interestrateswapmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap interestrateswapmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap gaap nondesignatedmemberus gaap othercurrentassetsmemberus gaap gaap nondesignatedmemberus gaap othercurrentassetsmemberus gaap gaap nondesignatedmemberus gaap othercurrentliabilitiesmemberus gaap gaap nondesignatedmemberus gaap othercurrentliabilitiesmemberus gaap gaap otherexpensememberus gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap otherexpensememberus gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap otherexpensememberus gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap otherexpensememberus gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap netinvestmenthedgingmemberus gaap designatedashedginginstrumentmembertmo gaap netinvestmenthedgingmemberus gaap designatedashedginginstrumentmembertmo gaap netinvestmenthedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap netinvestmenthedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap netinvestmenthedgingmemberus gaap otherexpensememberus gaap designatedashedginginstrumentmemberus gaap gaap netinvestmenthedgingmemberus gaap otherexpensememberus gaap designatedashedginginstrumentmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap otherexpensememberus gaap nondesignatedmemberus gaap gaap otherexpensememberus gaap nondesignatedmemberus gaap gaap interestrateswapmemberus gaap designatedashedginginstrumentmemberus gaap gaap gaap gaap gaap gaap lifesciencessolutionsmemberus gaap lifesciencessolutionsmemberus gaap coststoconformaccountingpoliciesmembertmo chargesforsalesofinventoriesrevaluedatacquisitionmembertmo transactioncostsrelatedtoacquisitionmembertmo productliabilityworkerscompensationandotherpersonalinjurymattersmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap united state security and exchange commissionwashington form annual report pursuant to section or of the security exchange act of for the fiscal year ended december or transition report pursuant to section or of the security exchange act of file number fisher scientific inc exact name of registrant specified in it charter state of incorporation employer identification no third avenuewaltham massachusetts address of principal executive office zip code registrant telephone number including area code registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon stock par valuetmonew york stock exchangefloating rate note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangesecurities registered pursuant to section of the act noneindicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month and ha been subject to filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation during the preceding month yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no of june the aggregate market value of the voting stock held by nonaffiliates of the registrant approximately based on the last reported sale of common stock on the new york stock exchange composite tape reporting system on june of february the registrant share of common stock outstanding document incorporated by referencesections of thermo fisher definitive proxy statement for the annual meeting of shareholder are incorporated by reference into part ii and iii of this report thermo fisher scientific inc annual report on form kfor the fiscal year ended december table of contentspagepart iitem risk unresolved staff legal mine safety iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity selected financial management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary change in and disagreement with accountant on accounting and financial control and other iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement form fisher scientific inc part iitem businessgeneral development of businessthermo fisher scientific inc also referred to in this document thermo fisher the company or the registrant is the world leader in serving science mission is to enable our customer to make the world healthier cleaner and safer we serve more customer working in pharmaceutical and biotech company hospital and clinical diagnostic lab university research institution and government agency well environmental industrial quality and process control setting our global team of more than colleague delivers unique combination of innovative technology purchasing convenience and pharmaceutical service through our industry leading brand including thermo scientific applied biosystems invitrogen fisher scientific unity lab service and patheon we continuously increase our depth of capability in technology software and service and leverage our extensive global channel to address our customer emerging need we this through organic investment in research and development and through acquisition for example in april we acquired within the laboratory product and service segment brammer bio expanding our contract manufacturing capability to include full range of viral vector development and manufacturing service our goal is to make our customer more productive in an increasingly competitive business environment and to allow them to solve challenge from complex research to improved patient care environmental and process monitoring and consumer safety thermo fisher is delaware corporation and wa incorporated in the company completed it initial public offering in and wa listed on the new york stock exchange in forward looking statementsforward looking statement within the meaning of section of the security exchange act of the exchange act are made throughout this annual report on form any statement contained herein that are not statement of historical fact may be deemed to be forward looking statement including without limitation statement regarding projection of revenue expense earnings margin tax rate tax provision cash flow pension and benefit obligation and funding requirement our liquidity position cost reduction restructuring activity new product and service development competitive strength or market position acquisition or divestiture growth decline and other trend in market we sell into new or modified law regulation and accounting pronouncement outstanding claim legal proceeding tax audit and assessment and other contingent liability foreign currency exchange rate and fluctuation in those rate general economic and capital market condition the timing of any of the foregoing assumption underlying any of the foregoing and any other statement that address event or development that thermo fisher intends or belief will or may occur in the future without limiting the foregoing the word belief anticipates plan expects seek estimate and similar expression are intended to identify forward looking statement although not all forward looking statement are accompanied by such word the company may elect to update forward looking statement in the future it specifically disclaims any obligation to do even if the company estimate change and reader not rely on those forward looking statement representing the company view of any date subsequent to the date of the filing of this report number of important factor could cause the result of the company to differ materially from those indicated by such forward looking statement including those detailed the heading risk factor in part item business segment and productswe report our business in four segment life science solution analytical instrument specialty diagnostics and laboratory product and service life science solution segmentthrough our life science solution segment we provide an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of disease these product and service are used by customer in pharmaceutical biotechnology agricultural clinical academic and government market life science solution includes four primary business bioscience genetic science clinical next generation sequencing and bioproduction biosciencesour bioscience business includes reagent instrument and consumables that help our customer conduct biological and medical research discover new drug and vaccine and in the case of specific product the diagnosis of disease fisher scientific inc business continued our bioscience offering include reagent instrument and consumables used for protein biology molecular biology sample preparation and cell imaging and analysis the portfolio includes antibody and product for protein purification detection modification and analysis and sequencing detection and purification product used for high content analysis of nucleic acid many of these product are also used in applied market including agriculture forensics diagnostics product development and toxicology research tool used for genetic engineering amplification quantification and analysis well rna isolation including stem cell reprogramming kit transfection reagent rna interference reagent along with gene editing tool and gene synthesis product cell culture medium reagent and plastic for preserving and growing mammalian cell which are used in many life science research application fluorescence based technology which facilitate the labeling of molecule for biological research and drug discovery these technology include wide range of cell analysis instrument including flow cytometers and imaging platform that enable fluorescence microscopy protein analysis product including pre cast electrophoresis gel for separating nucleic acid and protein and western blotting and staining tool genetic sciencesour genetic science business combine wide variety of instrument and related reagent used to provide high value genomic solution to assist customer decision in the research clinical and applied market our offering include real time pcr technology used to identify change in gene expression genotyping or protein on an individual gene by gene basis capillary electrophoresis ce sequencing core technology used in dna sequencing and fragment analysis and forensic analysis application and microarray technology used in gene expression genotyping and reproductive health our genetic analyzer served the foundational platform used to sequence the first human genome these system are used in variety of basic commercial and clinical research application clinical next generation sequencingour clinical next generation sequencing ng business focus on delivering simple fast and cost effective ng technology for range of application the business is focused on targeted sequencing solution for research use and the application of ng in oncology bioproductionour bioproduction business support developer and manufacturer of biological based therapeutic and vaccine with portfolio of premium solution and service focused on upstream cell culture downstream purification analytics for detection and quantitation of process product impurity and suite of single use solution spanning the biologics workflow our bioproduction offering include single use bioproduction solution that provide our customer with faster turnaround and set time minimal validation requirement reduced investment and running cost and increased flexibility of manufacturing capacity production cell culture medium solution which are used by leading biotechnology and pharmaceutical company to grow cell in controlled condition and enable large scale cgmp current good manufacturing practice manufacturing of drug and vaccine we also provide our customer with the associated service to optimize the productivity of these production platform chromatography product which deliver superior capacity and resolution for process scale bioseparations and offer broad set of scalable option for the purification of antibody antibody fragment and protein rapid molecular product that deliver accurate result in le than four hour for contaminant detection identification and quantitation scalable solution for the manufacture of cell therapy based drug fisher scientific inc business continued our doe ingalls offering include chemical distribution and supply chain service that provide primarily life science manufacturer with reliable secure supply chain for their chemical raw material analytical instrument segmentthrough our analytical instrument segment we provide broad offering of instrument consumables software and service that are used for range of application in the laboratory on the production line and in the field these product and service are used by customer in pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory this segment includes three primary business chromatography and mass spectrometry chemical analysis and material and structural analysis chromatography and mass spectrometryour chromatography and mass spectrometry business provides analytical instrumentation for organic and inorganic sample analysis across both applied technology and life science research these product are complemented by laboratory information management system lims chromatography data system cd database analytical tool automation system range of consumables such full line of chromatography column and range of sample preparation and separation product including auto sampler and multiplexing system chromatography is technique for separating identifying and quantifying individual chemical component of substance based on their specific physical and chemical characteristic our chromatography product line includes high performance liquid chromatography ion chromatography and gas chromatography system all of which are supported by our chromeleon chromatography data system software liquid chromatography lc system analyze complex sample matrix in liquid our high pressure liquid chromatography hplc and ultrahigh pressure liquid chromatography uhplc system offer high throughput and sensitivity and are sold either stand alone system or integrated with our mass spectrometer lc and lc these system are used for range of application from complex proteomic analysis to routine industrial quality assurance and quality control qa qc ion chromatography ic system separate ionic charged or highly polar molecule sugar and carbohydrate usually found in water based solution and typically detect them based on their electrical conductivity our ic product are used in wide range of application including scientific research and environmental testing well quality control in pharmaceutical food and beverage and other industrial process gas chromatography gc system analyze complex sample matrix in gas comprising both separation and detection technology separation technology is common to all gas chromatography analyzer and is paired with either conventional detector gc or with different type of mass spectrometer gc our gc offering includes triple stage quadrupole single stage quadrupole an orbitrap and an ion trap for range of application including food safety testing quantitative screening of environmental sample and complex molecular analysis elemental analysis spectrometer use atomic spectroscopy technique to identify trace concentration of element in liquid and solid sample primarily in environmental petrochemical food safety metallurgical geochemical and clinical toxicology research application these product are widely used in growth market such china india and latin america to support compliance with increasingly stringent international environmental and consumer safety regulation mass spectrometry is technique for analyzing chemical compound individually or in complex mixture by forming charged ion that are analyzed according to their mass to charge ratio in addition to molecular information each discrete chemical compound generates pattern that provides structurally identifiable information our comprehensive offering includes life science mass spectrometry system and inorganic mass spectrometry system well range of sample preparation and separation product including auto sampler and multiplexing system life science mass spectrometer include triple quadrupole and orbitrap technology our triple quadrupole system provide high performance quantitative analysis of chemical in biological fluid environmental sample and food matrix they are also used by the pharmaceutical industry for targeted quantitation during drug discovery our orbitrap technology provide high resolution and accurate mass capability for both research and applied market and are well suited for drug metabolism proteomics environmental analysis food safety toxicology and clinical research application we also offer comprehensive portfolio of instrument control and data analysis software to help customer simplify their workflow and obtain knowledge from often complex data fisher scientific inc business continued inorganic mass spectrometer include four product line isotope ratio mass spectrometry irms multi collector isotope ratio mass spectrometry mc irms inductively coupled plasma mass spectrometry icp and high resolution trace mass spectrometry hr trace these product are primarily used for qualitative and quantitative analysis of inorganic matter in range of application including environmental analysis material science and earth science chemical analysisour chemical analysis product fall into three main category material and mineral instrument field safety instrument and environmental and process instrument customer use these product to quickly and accurately analyze the composition of material to optimize workflow primarily in industrial application or to help them comply with governmental regulation and industry safety standard our product line range from those used on production line to improve quality and efficiency to portable system for rapid and real time chemical identification in the field or to analyze measure or respond to hazardous situation material and mineral instrument include production line process monitoring and control system for range of industrial application for example we offer on line instrument that analyze bulk material non invasively and in real time to improve quality control and ensure safe operation in mine or cement manufacturing plant well system that enable high speed weighing during bulk material handling we also offer gauging system that employ ionizing and non ionizing technology to measure the total thickness basis weight and coating thickness of flat sheet material such steel plastic foil rubber and glass we also offer on line analyzer based on variety of technology such ray imaging and ultra trace chemical detection to inspect packaged good for physical contaminant validate fill quantity or check for missing or broken part on line and at high speed in the food and beverage pharmaceutical production and packaging industry to maintain safety and quality standard field safety instrument are rugged handheld product that provide rapid precise real time analysis at the point of need our main product category are elemental analyzer optical analyzer and radiation detection instrument our portable elemental analyzer use ray fluorescence xrf technology for identifying metal alloy in scrap metal recycling qa qc precious metal analysis environmental analysis and lead screening in range of consumer product our portable optical analyzer utilize raman fourier transform infrared ftir and near infrared nir technology for use in the field by first responder and law enforcement and military personnel need to quickly and accurately identify chemical and explosive in critical safety and security situation other application include qa qc in pharmaceutical production and identification of counterfeit drug our radiation measurement product are used to monitor detect and identify specific form of radiation in nuclear power environmental industrial medical and security application our primary customer include national regional and local government agency responsible for monitoring cargo vehicle and people traveling across border these product are also used by first responder in safety and security situation and for worker safety in the nuclear power and other industrial market environmental and process instrument include fixed and portable instrumentation that help our customer protect people and the environment well comply with government regulation and industry safety standard our product are used by environmental regulatory agency and power plant operator to measure ambient air and stack gas emission for compliance with regulated emission standard for criterion pollutant gas our product are also used in ambient particulate monitoring application by customer in mining environment to provide continuous measurement and logging of real time concentration and median particle size of airborne dust smoke mist and fume to improve efficiency and increase worker safety in addition to our broad product offering we offer variety of specialized service to our customer including equipment servicing instrument calibration service asset management and training material and structural analysisour material and structural analysis business includes electron microscopy molecular spectroscopy and laboratory elemental analysis instrument that are used by customer in life science material science and industrial market to accelerate breakthrough discovery electron microscopy instrument include transmission electron microscope which provide imaging and characterization at the atomic scale with application in semiconductor development material science research and the characterization of protein structure and function we also offer scanning electron microscope which resolve feature from the optical regime to the nanometer length scale and are used for wide variety of application from material characterization in science and engineering to application in natural resource manufacturing and biological system our dualbeam focused ion beam scanning electron microscope system are used for sample fisher scientific inc business continued preparation characterization nanoprototyping and industrial failure analysis our focused ion beam microscope are used in range of process control failure analysis and material research application we also offer electrical failure analysis instrument which are used in root cause failure analysis and quality control microct instrument which are micro computed tomography solution for quantitative analysis of broad range of material providing visualization of large volume non destructively and visualization software that turn the data and image generated by broad range of instrument into visualization of the microscopic sample allowing quantitative analysis of material property molecular spectroscopy instrument are divided into four primary technique ftir raman nir and ultraviolet visible uv vi spectroscopy these technology are typically used in the laboratory to provide information on the structure of molecule to identify verify and quantify organic material in pharmaceutical biotechnology polymer chemical and forensic science our material characterization instrument include rheometer and extruders that measure viscosity elasticity processability and temperature related mechanical change of various material we also provide range of surface analysis instrument commonly used in the semiconductor metal coating and polymer industry product development and failure analysis tool laboratory elemental analysis instrument and analyzer use ray fluorescence xrf ray diffraction xrd and arc spark optical emission oes technique for accurate and precise analysis of bulk material in the metal cement mineral and petrochemical industry specialty diagnostics segmentour specialty diagnostics segment offer wide range of diagnostic test kit reagent culture medium instrument and associated product in order to serve customer in healthcare clinical pharmaceutical industrial and food safety laboratory our healthcare product are used to increase the speed and accuracy of diagnosis which improves patient care in more cost efficient manner this segment ha five primary business clinical diagnostics immunodiagnostics microbiology transplant diagnostics and our healthcare market channel in june the company sold it anatomical pathology business previously reported in this segment the business offered product primarily for cancer diagnosis and medical research in histology cytology and hematology application clinical diagnosticsour clinical diagnostics product include broad offering of liquid ready to use and lyophilized immunodiagnostic reagent kit calibrators control and calibration verification fluid in particular we provide product used for drug of abuse testing therapeutic drug monitoring including immunosuppressant drug testing thyroid hormone testing serum toxicology clinical chemistry immunology hematology coagulation glucose tolerance testing first trimester screening tumor marker testing and biomarkers testing for sepsis acute myocardial infarction and congestive heart failure we also private label many of our reagent and control for major in vitro diagnostics company through oem arrangement in many instance we will work with customer or partner to develop new product and application for their instrument platform we have developed one of the broadest menu for drug of abuse immunoassay we also provide broad offering of immunosuppressant drug immunoassay that can be used on variety of clinical chemistry analyzer our clinical chemistry system include analyzer and reagent to analyze and measure routine blood and urine chemistry such glucose and cholesterol and advanced testing for specific protein therapeutic drug monitoring and drug of abuse our diagnostic test range currently cover approximately different validated method we also provide pre and post analytical automation for preparation of blood specimen and analysis and specialty diagnostic test based on patented biomarkers for sepsis cardiovascular and pulmonary disease well intensive care treatment and prenatal screening immunodiagnosticsour immunodiagnostics offering include developing manufacturing and marketing complete blood test system to support the clinical diagnosis and monitoring of allergy asthma and autoimmune disease in addition we offer antibody test for approximately indication to help diagnose autoimmune disease such rheumatoid arthritis celiac disease lupus and scleroderma our product include immunocap for allergy and asthma test and elia for autoimmunity test microbiologyour microbiology offering include dehydrated and prepared culture medium collection and transport system instrumentation and consumables to detect pathogen in blood diagnostic and rapid direct specimen test quality control product and associated product for the microbiology laboratory our product help customer worldwide to diagnose fisher scientific inc business continued infectious disease determine appropriate antimicrobial therapy implement effective infection control program and detect microbial contamination of their product or manufacturing facility within the food and pharmaceutical industry our product are used to assure the safety and quality of consumer product by monitoring production environment raw material and end product for bacterial contamination and animal health in the dairy industry transplant diagnosticsour transplant diagnostics product include human leukocyte antigen hla typing and testing for the organ transplant market our diagnostic test are used by transplant center for tissue typing primarily to determine the compatibility of donor and recipient pre transplant and to detect the presence of antibody post transplant that can lead to transplant rejection these transplant diagnostic test are widely used across the transplant testing workflow to improve patient outcome our transplant diagnostic offering include several line of hla typing and antibody detection assay utilizing serological molecular enzyme linked immunosorbent assay elisa flow and multiplexing technology healthcare market channelour healthcare market channel offering include broad array of consumables diagnostic kit and reagent equipment instrument solution and service for hospital clinical laboratory reference laboratory physician office and other clinical testing facility these product are manufactured by thermo fisher and third party and are primarily used in clinical diagnosis laboratory product and service segmentour laboratory product and service segment offer virtually everything needed for the laboratory our unique combination of self manufactured and sourced product and extensive service offering enables our customer to focus on their core activity and help them to be more efficient productive and cost effective the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical trial logistics and commercial drug manufacturing we serve the pharmaceutical biotechnology academic government and other research and industrial market well the clinical laboratory through four key business laboratory product laboratory chemical research and safety market channel and pharma service laboratory productsour laboratory product are used primarily by pharmaceutical company for drug discovery and development and by biotechnology company and university for life science research to advance the prevention and cure of disease and enhance quality of life this offering consists of equipment accessory and service for sample preparation storage and protection and analysis laboratory equipment technology includes our leading laboratory refrigerator and freezer ultralow temperature freezer and cryopreservation storage tank for maintaining sample in cold environment to protect them from degradation we also offer temperature control product such heated bath circulators immersion cooler recirculating chiller water bath and dry bath in range of size temperature and configuration for life science analytical chemistry manufacturing and quality control application in addition we offer sample preparation and preservation equipment which protects our customer chemical and biological sample and support the growth of cell and organism in optimal condition such temperature carbon dioxide and humidity well incubator and related product we also offer centrifugation product which are used to separate biological matrix and inorganic material including microcentrifuges general use bench top centrifuge and floor model additionally we offer biological safety cabinet which enable technician to handle sample without risk to or their environment and without risk of cross contamination of sample water and laboratory product include water analysis instrument such meter electrode and solution for the measurement of ph ion conductivity dissolved oxygen turbidity and other key parameter in the lab and production line we also offer other laboratory equipment such water purification system shaker vacuum concentrators microbiological incubator oven furnace hotplate stirrer stirring hotplate and other related product laboratory plastic essential include leading offering of laboratory pipette tip and complementary range of handheld and automated pipetting system supporting low through high throughput activity these product optimize productivity and ergonomics and ensure accurate result we also offer sample preparation and storage product such centrifugation consumables well vial and organization system for ultralow temperature and cryogenic storage with specific product designed for low protein binding and low dna binding and container for packaging fisher scientific inc business continued life science and diagnostic reagent well for the storage and transport of bulk intermediate and active pharmaceutical ingredient additionally our offering include complete selection of clinical specimen collection product drug of abuse collection kit and environmental and food safety glass and plastic vial bottle and container plastic transfer pipette general purpose clinical laboratory consumables and container for breast milk collection storage and feeding primarily used in neo natal unit and by lactation specialist we also provide oem and custom kit assembly service for clinical and drug of abuse test kit laboratory chemicalsour laboratory chemical offering comprises broad range of chemical solvent and reagent supporting virtually every laboratory application from research to drug discovery and development and manufacturing this portfolio includes organic chemical used to synthesize new material essential laboratory chemical used by scientist to purify extract separate identify and manufacture product high purity analytical reagent bioreagents used in many different application from cell growth to detailed protein analysis novel chemical building block reactive intermediate and screening library used to accelerate drug discovery and precious metal salt and solution used in broad range of application highly specific reaction are desired we provide bulk volume of many product for scale up from research to development and customized service for chemical procurement processing production testing and packaging research and safety market channelour research and safety market channel serf academic pharmaceutical biotechnology government and industrial customer we go to market through our expert sale force segment relevant printed collateral and digital content in five language state of the art website www fishersci com containing full product content for more than million product and our global network of resellers and distributor we have an international network of warehouse in our primary market through which we maintain inventory and coordinate product delivery with specialized product vault and warehouse management system we are able to handle the complete range of product we offer to our customer our transportation capability include our dedicated fleet of delivery vehicle well parcel shipping capability that are closely integrated with our third party parcel carrier throughout the product delivery process we provide our customer with convenient access to comprehensive electronic system that offer automated catalog search product order and invoicing and payment capability our channel offer mix of product that are manufactured by thermo fisher by third party for on private label basis and by third party under their brand but offered for sale exclusively through we also offer broad range of third party product representing leading industry brand name on non exclusive basis our research product include complete offering of laboratory product ranging from capital equipment and instrument to chemical to consumable product our safety product include clean room and controlled environment supply personal protective equipment firefighting military and first responder equipment and supply and environmental monitoring and sampling equipment our education product include science related and laboratory product for the and secondary education market in addition to our broad product offering we offer variety of specialized service to our customer through our unity lab service team including training equipment servicing and asset management and dedicated supply management personnel we also offer scientific support service including desktop delivery coordination of instrument calibration and service and on site customer service pharma serviceswe provide the entire spectrum of development manufacturing and clinical trial service for both small molecule and large molecule pharmaceutical this includes development of suitable formulation and manufacturing process for the active pharmaceutical ingredient api or biologic ii technology transfer to scale up the manufacturing iii labeling packaging distribution and logistics for clinical trial and iv commercial scale manufacturing and packaging drug substance service our service offering address small molecule produced through chemical synthesis and large molecule such antibody and protein produced through mammalian cell culture we provide development and manufacturing service for small molecule apis and the biologically active component of pharmaceutical product under current good manufacturing practice cgmp condition from early development through commercial production drug product service we manufacture both small molecule and large molecule product for customer in conventional and specialized dosage form we differentiate by our breadth of dosage form and specialized fisher scientific inc business continued capability in both oral solid and sterile dosage form we provide wide spectrum of advanced formulation production and technical service and scientific expertise and solution from the early stage of product development to regulatory approval and commercial scale production clinical trial service we provide global service for pharmaceutical and biotechnology company engaged in clinical trial including comparator sourcing specialized packaging over encapsulation multi lingual and specialized labeling and distribution for phase through phase iv clinical trial biological specimen management and biobanking service specialty pharmaceutical logistics and clinical supply chain planning and management viral vector service we provide full range of viral vector development and manufacturing service for customer developing and commercializing gene and cell therapy including process development optimization scale up analytical development and qualification of viral vector for commercial manufacturing our breadth of vector platform includes the five widely used virus type providing extensive coverage across the gene and cell therapy landscape sale and marketingwe market and sell our product and service through direct sale force customer service professional electronic commerce third party distributor and various catalog we offer our product and service through leading brand including the thermo scientific brand offer customer in research diagnostics industrial and applied market complete range of high end analytical instrument well laboratory equipment software service consumables and reagent our portfolio of product includes innovative technology for mass spectrometry chromatography elemental analysis electron microscopy molecular spectroscopy sample preparation informatics chemical research and analysis cell culture bioprocess production cellular protein and molecular biology research allergy testing drug of abuse testing therapeutic drug monitoring testing microbiology well environmental monitoring and process control the applied biosystems brand offer customer in research clinical and applied market integrated instrument system reagent and software for genetic analysis our portfolio includes innovative technology for genetic sequencing and real time digital and end point polymerase chain reaction pcr that are used to determine meaningful genetic information in application such cancer diagnostics human identification testing and animal health well inherited and infectious disease the invitrogen brand offer life science customer broad range of consumables and instrument that accelerate research and ensure consistency of result our portfolio of product includes innovative solution for cellular analysis and biology flow cytometry cell culture protein expression synthetic biology molecular biology and protein biology fisher scientific is our channel brand offering customer complete portfolio of laboratory equipment and consumables chemical supply and service used in scientific research healthcare safety and education market these product are offered through an extensive network of direct sale professional segment relevant printed collateral and digital content state of the art website and supply chain management service unity lab service is our instrument and equipment service brand offering complete portfolio of service from enterprise level engagement to individual instrument and laboratory equipment regardless of the original manufacturer through our network of world class service and support personnel we provide service that are designed to help our customer improve productivity reduce cost and drive decision with better data patheon is our contract development and manufacturing brand representing the comprehensive offering of service that we provide to customer ranging from small biotech to large pharmaceutical company we support our customer development of innovative medicine including biologics gene therapy and vaccine by leveraging our expanding global network of facility we deliver high quality service at all stage of the drug lifecycle from discovery to development through clinical trial and commercial manufacturing we have approximately sale personnel including highly trained technical specialist who enable to better meet the need of our more technical end user we also provide customer with product standardization and other supply chain management service to reduce procurement cost fisher scientific inc business continued new product and research and developmentour business includes the development and introduction of new product and may include entry into new business segment we anticipate that we will continue to make significant expenditure for research and development we seek to provide continuing flow of innovative product to maintain and improve our competitive position raw materialsour management team belief that we have readily available supply of raw material for all of our significant product from various source we do not anticipate any difficulty obtaining the raw material essential to our business raw material and fuel price are subject to fluctuation due to market condition we employ many strategy including the use of alternative material to mitigate the effect of these fluctuation on our result patent license and trademarkspatents are important in many aspect of our business no particular patent or related group of patent is so important however that it loss would significantly affect our operation whole where appropriate we seek patent protection for invention and development made by our personnel that are incorporated into our product or otherwise fall within our field of interest patent right resulting from work sponsored by outside party do not always accrue exclusively to the company and may be limited by agreement or contract we protect some of our technology trade secret and where appropriate we use trademark or register trademark used in connection with product we also enter into license agreement with others to grant and or receive right to patent and know seasonal influencesrevenues in the fourth quarter are historically stronger than in other quarter due to the capital spending pattern of industrial pharmaceutical and government customer sale of flu test and related diagnostic product vary quarter to quarter and year to year based on the severity and duration of each period flu season sale of allergy test vary quarter to quarter and year to year based on the severity and duration of each period airborne pollen allergen working capital requirementsthere are no special inventory requirement or credit term extended to customer that would have material adverse effect on our working capital dependency on single customerthere is no single customer the loss of which would have material adverse effect on our business no customer accounted for more than of our total revenue in any of the past three year backlogour backlog of firm order at year end and wa follows in million science solution analytical specialty laboratory product and elimination we believe that approximately of our backlog at the end of will be filled during government contractsalthough the company transacts business with various government agency no government contract is of such magnitude that renegotiation of profit or termination of the contract at the election of the government agency would have material adverse effect on the company financial result fisher scientific inc business continued competitionthe company encounter aggressive and able competition in virtually all of the market we serve of the diversity of our product and service we face many different type of competitor and competition our competitor include broad range of manufacturer and third party distributor competitive climate in many of the market we serve are characterized by changing technology and customer demand that require continuing research and development our success primarily depends on the following factor technical performance and advance in technology that result in new product and improved price performance ratio product differentiation availability and reliability the depth of our capability our reputation among customer quality provider of product and service customer service and support active research and application development program and relative price of our product and service environmental matterswe are subject to various law and governmental regulation concerning environmental matter and employee safety and health in the united state and other country federal environmental legislation that affect includes the toxic substance control act the resource conservation and recovery act the clean air act the clean water act the safe drinking water act and the comprehensive environmental response compensation and liability act cercla we are also subject to regulation by the occupational safety and health administration osha concerning employee safety and health matter the united state environmental protection agency usepa osha and other federal agency have the authority to promulgate regulation that have an effect on our operation in addition to these federal activity various state have been delegated certain authority under the aforementioned federal statute well authority over these matter under state law many state and local government have adopted environmental and employee safety and health law and regulation some of which are similar to federal requirement number of our operation involve the handling manufacturing use or sale of substance that are or could be classified toxic or hazardous material within the meaning of applicable law consequently some risk of environmental harm is inherent in our operation and product it is with other company engaged in similar business our expense for environmental requirement are incurred generally for ongoing compliance and historical remediation matter based on current information we believe that these compliance cost are not material for historical remediation obligation our expenditure relate primarily to the cost of permitting installing and operating and maintaining groundwater treatment system and other remedial measure our fair lawn and somerville new jersey facility entered into administrative consent order with the new jersey department of environmental protection in to maintain groundwater remediation activity at these site and are currently under the state licensed site remediation professional program the owner of the fair lawn facility we are listed potentially responsible party for remediation within an area called the fair lawn wellfields superfund site and in the company and certain other party entered into consent order with the usepa to complete remedial investigation feasibility study in the usepa issued record of decision including the scope of required remediation work based on finding of this study in the company and another responsible party signed proposed consent decree that once approved by the court requires the party to finance and perform the required remediation work with usepa oversight in our life technology subsidiary entered into consent decree with the usepa and other responsible party to implement groundwater remedy at the former davis landfill superfund site in smithfield rhode island we record accrual for environmental liability based on current interpretation of environmental law and regulation when it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated we calculate estimate based upon several factor including report prepared by environmental specialist and management knowledge and experience with these environmental matter we include in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site accrued liability for environmental matter totaled million at december these environmental liability do not include third party recovery to which we may be entitled we believe that our accrual is adequate for the environmental liability we currently expect to incur result we believe that our ultimate liability with respect to environmental matter will not have material adverse effect on our financial position result of fisher scientific inc business continued operation or cash flow however we may be subject to remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology change in the conduct of our operation and the effect of change in accounting rule which could have material adverse effect on our financial position result of operation or cash flow regulatory affairsour operation and some of the product we offer are subject to number of complex and stringent law and regulation governing the production handling transportation and distribution of chemical drug and other similar product including the operating and security standard of the food and drug administration the drug enforcement administration the bureau of alcohol tobacco firearm and explosive and various state board of pharmacy well comparable state and foreign agency thermo fisher business also include export and import activity we are subject to pertinent law enforced by the department of commerce state and treasury in addition our logistics activity must comply with the rule and regulation of the department of transportation the federal aviation administration and similar foreign agency while we believe we are in compliance in all material respect with such law and regulation any noncompliance could result in substantial fine or otherwise restrict our ability to provide competitive distribution service and thereby have an adverse effect on our financial condition to date none ha had material impact on our operation we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company business with the government we are also subject to investigation for compliance with the regulation governing government contract failure to comply with these regulation could result in suspension of these contract criminal civil and administrative penalty or debarment number of employeeswe have more than employee available informationthe company file annual quarterly and current report proxy statement and other document with the security and exchange commission sec under the exchange act the sec maintains website that contains report proxy and information statement and other information that issuer including the company file electronically with the sec the public can obtain any document that we file with the sec at www sec gov we also make available free of charge on or through our website at www thermofisher com our annual report on form quarterly report on form current report on form and if applicable amendment to those report filed or furnished pursuant to section of the exchange act soon reasonably practicable after we electronically file such material with or furnish it to the sec in addition paper copy of these document may be obtained free of charge by writing to the company care of it investor relation department at our principal executive office located at third avenue waltham massachusetts fisher scientific inc business continued information about our executive officersnameagepresent title fiscal year first became executive officer other position heldmarc chairman president and chief executive officer president and chief executive officer chief operating officer executive vice president mark executive vice president and chief operating officer executive vice president and president life science solution president and chief operating officer life technology corporation michel executive vice president senior vice president and president pharma service president and chief operating officer patheon managing director jll partner michael senior vice president and general counsel executive vice president and group general counsel luxottica group syed senior vice president and president region senior vice president asia pacific and emerging market stephen senior vice president and chief financial officer vice president financial operation peter vice president and chief accounting officer corporate controller jll partner is private equity firm focused on healthcare item risk factorsset forth below are the risk that we believe are material to our investor this section contains forward looking statement you should refer to the explanation of the qualification and limitation on forward looking statement in item business under the caption forward looking statement we must develop new product adapt to rapid and significant technological change and respond to introduction of new product by competitor to remain competitive our growth strategy includes significant investment in and expenditure for product development we sell our product in several industry that are characterized by rapid and significant technological change frequent new product and service introduction and enhancement and evolving industry standard competitive factor include technological innovation price service and delivery breadth of product line customer support business capability and the ability to meet the special requirement of customer our competitor may adapt more quickly to new technology and change in customer requirement than we can without the timely introduction of new product service and enhancement our product and service will likely become technologically obsolete over time in which case our revenue and operating result would suffer many of our existing product and those under development are technologically innovative and require significant planning design development and testing at the technological product and manufacturing process level our customer use many of our product to develop test and manufacture their own product result we must anticipate industry trend and develop product in advance of the commercialization of our customer product if we fail to adequately predict our customer need and future activity we may invest heavily in research and development of product and service that do not lead to significant revenue it may be difficult for to implement our strategy for improving internal growth our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market could diminish demand for our product and service which would adversely affect our result of operation and financial condition to address this issue we are pursuing number of strategy to improve our internal growth including strengthening our presence in selected geographic market allocating research and development funding to product with higher growth prospect developing new application for our technology expanding our service offering fisher scientific inc risk factor continued continuing key customer initiative combining sale and marketing operation in appropriate market to compete more effectively finding new market for our product and continuing the development of commercial tool and infrastructure to increase and support cross selling opportunity of product and service to take advantage of our depth in product offering we may not be able to successfully implement these strategy and these strategy may not result in the expected growth of our business our business is affected by general economic condition and related uncertainty affecting market in which we operate our business is affected by general economic condition both inside and outside the if the global economy and financial market or economic condition in europe the or other key market are unstable it could adversely affect the business result of operation and financial condition of the company and it customer distributor and supplier having the effect of reducing demand for some of our product increasing the rate of order cancellation or delay increasing the risk of excess and obsolete inventory increasing pressure on the price for our product and service causing supply interruption which could disrupt our ability to produce our product and creating longer sale cycle and greater difficulty in collecting sale proceeds our growth could suffer if the market into which we sell our product and service decline do not grow anticipated or experience cyclicality our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market could diminish demand for our product and service which would adversely affect our financial statement certain of our business operate in industry that may experience periodic cyclical downturn demand for some of our product depends on capital spending policy of our customer and on government funding policy our customer include pharmaceutical and chemical company laboratory university healthcare provider government agency and public and private research institution many factor including public policy spending priority available resource and product and economic cycle have significant effect on the capital spending policy of these entity spending by some of these customer fluctuates based on budget allocation and the timely passage of the annual federal budget an impasse in federal government budget decision could lead to substantial delay or reduction in federal spending economic political foreign currency and other risk associated with international sale and operation could adversely affect our result of operation international market contribute substantial portion of our revenue and we intend to continue expanding our presence in these region the exposure to fluctuation in currency exchange rate take on different form international revenue and cost are subject to the risk that fluctuation in exchange rate could adversely affect our reported revenue and profitability when translated into dollar for financial reporting purpose these fluctuation could also adversely affect the demand for product and service provided by multinational corporation our business occasionally invoice third party customer in currency other than the one in which they primarily do business the functional currency movement in the invoiced currency relative to the functional currency could adversely impact our cash flow and our result of operation our international sale grow exposure to fluctuation in currency exchange rate could have larger effect on our financial result in currency translation had an unfavorable effect of million on revenue due to the strengthening of the dollar relative to other currency in which the company sell product and service in addition many of our employee contract manufacturer supplier job function outsourcing activity and manufacturing facility are located outside the united state accordingly our future result could be harmed by variety of factor including interruption to transportation flow for delivery of part to and finished good to our customer change in specific country or region political economic or other condition change in diplomatic and trade relationship including new tariff trade protection measure import or export licensing requirement trade embargo and sanction and other trade barrier fisher scientific inc risk factor continued tariff imposed by the on good from other country and tariff imposed by other country on good including the tariff recently adopted by the government on various import from china and by the chinese government on certain good the impact of public health epidemic on the global economy such the coronavirus currently impacting china negative consequence from change in tax law difficulty in staffing and managing widespread operation differing labor regulation differing protection of intellectual property unexpected change in regulatory requirement and geopolitical uncertainty or turmoil including terrorism and war for example on january the united kingdom formally withdrew from the european union or eu and entered transition period during which it will negotiate trade deal with the eu this withdrawal ha created political and economic uncertainty particularly in the united kingdom and the eu and this uncertainty may last for year our business could be affected during this period of uncertainty and perhaps longer by the impact of the united kingdom withdrawal from the eu in addition our business could be negatively affected by new trade agreement the united kingdom and other country including the united state and by the possible imposition of trade or other regulatory barrier in the united kingdom these possible negative impact and others resulting from the united kingdom withdrawal from the eu may adversely affect our operating result and our customer business our inability to protect our intellectual property could have material adverse effect on our business in addition third party may claim that we infringe their intellectual property and we could suffer significant litigation or licensing expense result we place considerable emphasis on obtaining patent and trade secret protection for significant new technology product and process because of the length of time and expense associated with bringing new product through the development process and into the marketplace our success depends in part on our ability to develop patentable product and obtain and enforce patent protection for our product both in the united state and in other country we own numerous and foreign patent and we intend to file additional application appropriate for patent covering our product patent may not be issued for any pending or future patent application owned by or licensed to and the claim allowed under any issued patent may not be sufficiently broad to protect our technology any issued patent owned by or licensed to may be challenged invalidated or circumvented and the right under these patent may not provide with competitive advantage in addition competitor may design around our technology or develop competing technology intellectual property right may also be unavailable or limited in some foreign country which could make it easier for competitor to capture increased market position we could incur substantial cost to defend ourselves in suit brought or in suit in which we may assert our patent right against others an unfavorable outcome of any such litigation could materially adversely affect our business and result of operation we also rely on trade secret and proprietary know how with which we seek to protect our product in part by confidentiality agreement with our collaborator employee and consultant these agreement may be breached and we may not have adequate remedy for any breach in addition our trade secret may otherwise become known or be independently developed by our competitor third party may assert claim against to the effect that we are infringing on their intellectual property right in the event that claim relating to intellectual property is asserted against or third party not affiliated with hold pending or issued patent that relate to our product or technology we may seek license to such intellectual property or challenge those patent however we may be unable to obtain these license on commercially reasonable term if at all and our challenge of the patent may be unsuccessful our failure to obtain the necessary license or other right could prevent the sale manufacture or distribution of our product and therefore could have material adverse effect on our business financial condition and result of operation change in governmental regulation may reduce demand for our product or increase our expense we compete in many market in which we and our customer must comply with federal state local and international regulation such environmental health and safety and food and drug regulation we develop configure and market our product to meet customer need created by those regulation any significant change in regulation could reduce demand for our product or increase our expense for example we manufacture pharmaceutical and many of our instrument are marketed to the fisher scientific inc risk factor continued pharmaceutical industry for use in discovering and developing drug change in the food and drug administration regulation of the drug discovery and development process could have an adverse effect on the demand for these product our pharma service offering are highly complex and if we are unable to provide quality and timely offering to our customer our business could suffer our pharma service offering are highly exacting and complex due in part to strict quality and regulatory requirement our operating result in this business depend on our ability to execute and when necessary improve our quality management strategy and system and our ability to effectively train and maintain our employee base with respect to quality management failure of our quality control system could result in problem with facility operation or preparation or provision of product in each case such problem could arise for variety of reason including equipment malfunction failure to follow specific protocol and procedure problem with raw material or environmental factor and damage to or loss of manufacturing operation such problem could affect production of particular batch or series of batch of product requiring the destruction of such product or halt of facility production altogether in addition our failure to meet required quality standard may result in our failure to timely deliver product to our customer which in turn could damage our reputation for quality and service any such failure could among other thing lead to increased cost lost revenue reimbursement to customer for lost drug product registered intermediate registered starting material and active pharmaceutical ingredient other customer claim damage to and possibly termination of existing customer relationship time and expense spent investigating the cause and depending on the cause similar loss with respect to other batch or product production problem in our drug and biologic manufacturing operation could be particularly significant because the cost of raw material for such manufacturing is often high if problem in preparation or manufacture of product or failure to meet required quality standard for that product are not discovered before such product is released to the market we may be subject to adverse regulatory action including product recall product seizure injunction to halt manufacture and distribution restriction on our operation civil sanction including monetary sanction and criminal action in addition such problem or failure could subject to litigation claim including claim from our customer for reimbursement for the cost of lost or damaged active pharmaceutical ingredient the cost of which could be significant we are subject to product and other liability risk for which we may not have adequate insurance coverage we may be named defendant in product liability lawsuit which may allege that product or service we have provided from our pharma service offering have resulted or could result in an unsafe condition or injury to consumer additionally product currently or previously sold by our environmental and process instrument and radiation measurement and security instrument business include fixed and portable instrument used for chemical radiation and trace explosive detection these product are used in airport embassy cargo facility border crossing and other high threat facility for the detection and prevention of terrorist act if any of these product to malfunction it is possible that explosive or radioactive material could fail to be detected by our product which could lead to product liability claim there are also many other factor beyond our control that could lead to liability claim such the reliability and competence of the customer operator and the training of such operator any such product liability claim brought against could be significant and any adverse determination may result in liability in excess of our insurance coverage although we carry product liability insurance we can not be certain that our current insurance will be sufficient to cover these claim or that it can be maintained on acceptable term if at all our inability to complete any pending acquisition or to successfully integrate any new or previous acquisition could have material adverse effect on our business our business strategy includes the acquisition of technology and business that complement or augment our existing product and service certain acquisition may be difficult to complete for number of reason including the need for antitrust and or other regulatory approval any acquisition we may complete may be made at substantial premium over the fair value of the net identifiable asset of the acquired company further we may not be able to integrate acquired business successfully into our existing business make such business profitable or realize anticipated cost saving or synergy if any from these acquisition which could adversely affect our business moreover we have acquired many company and business result of these acquisition we recorded significant goodwill and indefinite lived intangible asset primarily tradenames on our balance sheet which amount to approximately billion and billion respectively of december in addition we have definite lived intangible asset totaling billion of december we ass the realizability of goodwill and indefinite lived intangible asset annually well whenever event or change in circumstance indicate that these asset may be impaired we ass the realizability of definite lived intangible asset whenever event or change in circumstance indicate that these asset may be impaired these event or circumstance would generally include operating loss or significant decline in earnings associated with the acquired business or asset our ability to realize the value of the goodwill and intangible asset will depend on the future cash flow of these business these cash flow in turn depend in part on how well we have integrated these business fisher scientific inc risk factor continued if we are not able to realize the value of the goodwill and intangible asset we may be required to incur material charge relating to the impairment of those asset we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company doing business with the government the law governing government contract differ from the law governing private contract and government contract may contain pricing term and condition that are not applicable to private contract we are also subject to investigation for compliance with the regulation governing government contract failure to comply with these regulation could result in suspension of these contract criminal civil and administrative penalty or debarment because we compete directly with certain of our larger customer and product supplier our result of operation could be adversely affected in the short term if these customer or supplier abruptly discontinue or significantly modify their relationship with our largest customer in the laboratory product business is also significant competitor our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customer result in discontinuation of their purchase from in addition we manufacture product that compete directly with product that we source from third party supplier we also source competitive product from multiple supplier our business could be adversely affected in the short term if any of our large third party supplier abruptly discontinues selling product to because we rely heavily on third party package delivery service significant disruption in these service or significant increase in price may disrupt our ability to ship product increase our cost and lower our profitability we ship significant portion of our product to our customer through independent package delivery company such federal express in the and dhl in europe we also maintain small fleet of vehicle dedicated to the delivery of our product and ship our product through other carrier including national and regional trucking firm overnight carrier service and the postal service if one or more of these third party package delivery provider were to experience major work stoppage preventing our product from delivered in timely fashion or causing to incur additional shipping cost we could not pas on to our customer our cost could increase and our relationship with certain of our customer could be adversely affected in addition if one or more of these third party package delivery provider were to increase price and we were not able to find comparable alternative or make adjustment in our delivery network our profitability could be adversely affected we are required to comply with wide variety of law and regulation and are subject to regulation by various federal state and foreign agency we are subject to various local state federal foreign and transnational law and regulation which include the operating and security standard of the federal drug administration the fda the drug enforcement agency the dea various state board of pharmacy state health department the department of health and human service the dhhs the european medicine agency the ema in europe the eu member state and other comparable agency and in the future any change to such law and regulation could adversely affect in particular we are subject to law and regulation concerning current good manufacturing practice and drug safety our subsidiary may be required to register for permit and or license with and may be required to comply with the law and regulation of the dea the fda the dhhs foreign agency including the ema and other various state board of pharmacy state health department and or comparable state agency well certain accrediting body depending upon the type of operation and location of product distribution manufacturing and sale the manufacture distribution and marketing of many of our product and service including medical device and pharma service are subject to extensive ongoing regulation by the fda the dea the ema and other equivalent local state federal and non regulatory authority in addition we are subject to inspection by these regulatory authority failure by or by our customer to comply with the requirement of these regulatory authority including without limitation remediating any inspectional observation to the satisfaction of these regulatory authority could result in warning letter product recall or seizure monetary sanction injunction to halt manufacture and distribution restriction on our operation civil or criminal sanction or withdrawal of existing or denial of pending approval including those relating to product or facility in addition such failure could expose to contractual or product liability claim contractual claim from our customer including claim for reimbursement for lost or damaged active pharmaceutical ingredient well ongoing remediation and increased compliance cost any or all of which could be significant we are the sole manufacturer of number of pharmaceutical for many of our customer and negative regulatory event could impact our customer ability to provide product to their customer we are also subject to variety of federal state local and international law and regulation that govern among other thing the handling transportation and manufacture of substance that could be classified hazardous and we are required to fisher scientific inc risk factor continued comply with various import law and export control and economic sanction law which may affect our transaction with certain customer in certain circumstance export control and economic sanction regulation may prohibit the export of certain product service and technology in other circumstance we may be required to obtain an export license before exporting the controlled item compliance with the various import law that apply to our business can restrict our access to and increase the cost of obtaining certain product and at time can interrupt our supply of imported inventory any noncompliance by with applicable law and regulation or the failure to maintain renew or obtain necessary permit and license could result in criminal civil and administrative penalty and could have an adverse effect on our result of operation our reputation ability to do business and financial statement may be impaired by improper conduct by any of our employee agent or business partner we have internal control and compliance system to protect the company against act committed by employee agent or business that we acquire that would violate and or non law including the law governing payment to government official bribery fraud kickback and false claim pricing sale and marketing practice conflict of interest competition employment practice and workplace behavior export and import compliance money laundering and data privacy but we can not provide assurance that these control and system will prevent every such wrongful act in particular the foreign corrupt practice act the bribery act and similar anti bribery law in other jurisdiction generally prohibit company and their intermediary from making improper payment to government official for the purpose of obtaining or retaining business and we operate in many part of the world that have experienced governmental corruption to some degree any such improper action or allegation of such act could damage our reputation and subject to civil or criminal investigation in the united state and in other jurisdiction and related shareholder lawsuit could lead to substantial civil and criminal monetary and nonmonetary penalty and could cause to incur significant legal and investigatory fee in addition the government may seek to hold liable for violation committed by company which we acquire we also rely on our supplier to adhere to our supplier standard of conduct and material violation of such standard of conduct could occur that could have material effect on our business reputation and financial statement natural disaster public health crisis political crisis and other catastrophic event or other event outside of our control may disrupt our facility or the facility of third party on which we depend and could impact customer spending we have significant operation in california near major earthquake fault which make susceptible to earthquake risk an earthquake or other natural disaster such fire or hurricane or power shortage or outage could disrupt our operation or impair our critical system any of these disruption or other event outside of our control such strike or other labor unrest could have an adverse effect on our result of operation in addition if any of our facility including our manufacturing or warehouse facility or the facility of our supplier third party service provider or customer is affected by natural disaster such earthquake tsunami power shortage or outage flood or monsoon public health crisis such pandemic and epidemic political crisis such terrorism war political instability or other conflict or other event outside of our control such strike or other labor unrest our result of operation could be adversely affected moreover these type of event could negatively impact customer spending in the impacted region or depending upon the severity globally which could also adversely impact our operating result for example in december strain of coronavirus surfaced in wuhan china which could have material adverse effect on our business and result of operation the effect could include restriction on our ability to travel to support our site in china or our customer located there disruption in our ability to distribute product and or temporary closure of our facility in china or the facility of our supplier or customer related disruption inside or outside of china to our operation or the operation of our supplier or customer would likely impact our sale and operating result at this point the extent to which the coronavirus may impact our result of operation is uncertain fluctuation in our effective tax rate may adversely affect our result of operation and cash flow global company we are subject to taxation in numerous country state and other jurisdiction in preparing our financial statement we record the amount of tax that is payable in each of the country state and other jurisdiction in which we operate our future effective tax rate however may be lower or higher than experienced in the past due to numerous factor including change in the mix of our profitability from country to country change in accounting for income tax and recently enacted and future change in tax law in jurisdiction in which we operate any of these factor could cause to experience an effective tax rate significantly different from previous period or our current expectation which could have an adverse effect on our business result of operation and cash flow we may incur unexpected cost from increase in fuel and raw material price which could reduce our earnings and cash flow our primary commodity exposure are for fuel petroleum based resin and steel while we may seek to minimize the impact of price increase through higher price to customer and various cost saving measure our earnings and cash flow could be adversely affected in the event these measure are insufficient to cover our cost our reliance upon sole or limited source of supply for certain material or component could cause production interruption delay and inefficiency some of our business purchase certain material from sole or limited source supplier for reason of quality assurance regulatory requirement cost effectiveness availability or uniqueness of design if fisher scientific inc risk factor continued these or other supplier encounter financial operating or other difficulty or if our relationship with them change we might not be able to quickly establish or qualify replacement source of supply the supply chain for our business could also be disrupted by supplier capacity constraint bankruptcy or exiting of the business for other reason decreased availability of key raw material or commodity and external event such natural disaster pandemic health issue war terrorist action governmental action and legislative or regulatory change any of these factor could result in production interruption delay extended lead time and inefficiency significant disruption in or breach in security of our information technology system or violation of data privacy law could adversely affect our business part of our ongoing effort to upgrade our current information system we periodically implement new enterprise resource planning software and other software application to manage certain of our business operation we implement and add functionality problem could arise that we have not foreseen such problem could disrupt our ability to provide quote take customer order and otherwise run our business in timely manner when we upgrade or change system we may suffer interruption in service loss of data or reduced functionality in addition if our new system fail to provide accurate pricing and cost data our result of operation and cash flow could be adversely affected we also rely on our information technology system to process transmit and store electronic information including sensitive data such confidential business information and personally identifiable data relating to employee customer and other business partner and to manage or support variety of critical business process and activity such interacting with supplier selling our product and service fulfilling order and billing collecting and making payment shipping product providing service and support to customer tracking customer activity fulfilling contractual obligation and otherwise conducting business our system may be vulnerable to damage or interruption from natural disaster power loss telecommunication failure terrorist attack computer hacker computer virus ransomware phishing computer denial of service attack unauthorized access to customer or employee data or company trade secret and other attempt to harm our system certain of our system are not redundant and our disaster recovery planning is not sufficient for every eventuality despite any precaution we may take such problem could result in among other consequence interruption in our service which could harm our reputation and financial result any of the cyber attack breach or other disruption or damage described if significant could materially interrupt our operation delay production and shipment result in theft of our and our customer intellectual property and trade secret damage customer business partner and employee relationship and our reputation or result in defective product or service legal claim and proceeding liability and penalty under privacy law and increased cost for security and remediation each of which could adversely affect our business and financial result if we are unable to maintain reliable information technology system and appropriate control with respect to global data privacy and security requirement and prevent data breach we may suffer regulatory consequence in addition to business consequence global organization we are subject to data privacy and security law regulation and customer imposed control in numerous jurisdiction result of having access to and processing confidential personal and or sensitive data in the course of our business for example in the united state individual state regulate data breach and security requirement and multiple governmental body assert authority over aspect of the protection of personal privacy european law require to have an approved legal mechanism to transfer personal data of europe and the eu general data protection regulation imposes significantly stricter requirement in how we collect and process personal data several country such china and russia have passed law that require personal data relating to their citizen to be maintained on local server and impose additional data transfer restriction government enforcement action can be costly and interrupt the regular operation of our business and data breach or violation of data privacy law can result in fine reputational damage and civil lawsuit any of which may adversely affect our business reputation and financial statement our debt may restrict our investment opportunity or limit our activity of december we had approximately billion in outstanding indebtedness in addition we have availability to borrow under revolving credit facility that provides for up to billion of unsecured multi currency revolving credit we may also obtain additional long term debt and line of credit to meet future financing need which would have the effect of increasing our total leverage our leverage could have negative consequence including increasing our vulnerability to adverse economic and industry condition limiting our ability to obtain additional financing and limiting our ability to acquire new product and technology through strategic acquisition our ability to make scheduled payment refinance our obligation or obtain additional financing will depend on our future operating performance and on economic financial competitive and other factor beyond our control our business may not generate sufficient cash flow to meet our obligation if we are unable to service our debt refinance our existing debt or obtain additional financing we may be forced to delay strategic acquisition capital expenditure or research and development expenditure fisher scientific inc risk factor continued additionally the agreement governing our debt require that we maintain certain financial ratio and contain affirmative and negative covenant that restrict our activity by among other limitation limiting our ability to incur additional indebtedness merge or consolidate with other entity make investment create lien sell asset and enter into transaction with affiliate the covenant in our revolving credit facility the facility include consolidated leverage ratio total debt to consolidated ebitda and consolidated interest coverage ratio consolidated ebitda to consolidated interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain maximum consolidated leverage ratio of the company ha also agreed that so long any lender ha any commitment under the facility or any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated interest coverage ratio of of the last day of any fiscal quarter our ability to comply with these financial restriction and covenant is dependent on our future performance which is subject to prevailing economic condition and other factor including factor that are beyond our control such foreign exchange rate and interest rate our failure to comply with any of these restriction or covenant may result in an event of default under the applicable debt instrument which could permit acceleration of the debt under that instrument and require to prepay that debt before it scheduled due date also an acceleration of the debt under certain of our debt instrument would trigger an event of default under other of our debt instrument item unresolved staff commentsnone item propertiesthe company owns and lease office engineering laboratory production and warehouse space throughout the world item legal proceedingsthere are various lawsuit and claim against the company involving product liability intellectual property employment and commercial issue see note to our consolidated financial statement commitment and contingency item mine safety disclosuresnot applicable part iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity securitiesmarket price of common stockour common stock is traded on the new york stock exchange under the symbol tmo holder of common stockas of february the company had holder of record of it common stock this doe not include holding in street or nominee name fisher scientific inc issuer purchase of equity securitiesa summary of the share repurchase activity for the company fourth quarter of follows periodtotal number of share purchasedaverage price paid per sharetotal number of share purchased part of publicly announced plan or program maximum dollar amount of share that may yet be purchased under the plan or program in million fiscal october sep nov fiscal november nov nov fiscal december dec dec total fourth quarter on september the board of director authorized the repurchase of up to billion of the company common stock all of the share of common stock repurchased by the company during the fourth quarter of were purchased under this program on november the board of director replaced the existing authorization to repurchase the company common stock of which million wa remaining with new authorization to repurchase up to billion of the company common stock at february authorization remained for billion of future repurchase of the company common stock item selected financial data in million except per share amount statement of income data revenue income from continuing net earnings per share from continuing operation earnings per share balance sheet data total asset long term cash dividend declared per common share the caption restructuring and other cost income in the note below includes amount charged to cost of revenue primarily for the sale of inventory revalued at the date of acquisition and charge credit to selling general and administrative expense primarily for significant acquisition transaction cost reflects million of pre tax income from gain on sale of business net of restructuring and other cost and million of pre tax loss on the early extinguishment of debt reflects million of pre tax charge for restructuring and other cost reflects million of pre tax charge for restructuring and other cost also reflects the acquisition of patheon in august reflects million of pre tax charge for restructuring and other cost also reflects the acquisition of affymetrix inc in march and fei company in september reflects million of pre tax charge for restructuring and other cost fisher scientific inc item management discussion and analysis of financial condition and result of operationsreference is made throughout this management discussion and analysis of financial condition and result of operation to note to the consolidated financial statement which begin on page of this report management discussion and analysis of financial condition and result of operation for is included in item of the company annual report on form filed with the security and exchange commission overviewthe company develops manufacture and sell broad range of product that are sold worldwide the company expands the product line and service it offer by developing and commercializing it own technology and by making strategic acquisition of complementary business the company operation fall into four segment see note life science solution analytical instrument specialty diagnostics and laboratory product and service recent acquisition and divestiturethe company strategy is to augment internal growth at existing business with complementary acquisition the company principal recent acquisition and divestiture are described below on october the company acquired within the life science solution segment becton dickinson and company advanced bioprocessing business for million in cash this north america based business add complementary cell culture product that expand the segment bioproduction offering to help customer increase yield during production of biologic drug the advanced bioprocessing business reported revenue of million in on april the company acquired within the laboratory product and service segment brammer bio for approximately billion in cash brammer bio is leading viral vector contract development and manufacturing organization for gene and cell therapy the acquisition expands the segment contract manufacturing capability brammer bio reported revenue of approximately million in on june the company sold it anatomical pathology business to phc holding corporation for billion net of cash divested the business wa part of the specialty diagnostics segment the sale of this business resulted in pre tax gain of approximately million included in restructuring and other income cost net revenue in through the date of sale and the full year of the business sold were approximately million and million respectively net of retained sale through the company healthcare market and research and safety market channel business overview of result of operation and liquidity dollar in million science solution analytical specialty laboratory product and elimination sale in were billion an increase of billion from sale increased million due to acquisition net of divestiture the unfavorable effect of currency translation resulted in decrease in revenue of million in aside from the effect of acquisition divestiture and currency translation revenue increased billion primarily due to increased demand sale to customer in each of the company primary end market grew with particular strength in sale to customer in the biotech and pharmaceutical industry sale growth wa strong in each of the company primary geographic area in in the fourth quarter of sale to industrial customer declined and sale growth in asia wa modest due to weaker end market condition off of strong fourth quarter in fisher scientific inc management discussion and analysis of financial condition and result of operationsoverview of result of operation and liquidity continued in total company operating income and operating income margin were billion and respectively compared with billion and respectively in the increase in operating income wa primarily due to profit on higher sale the gain on the sale of the anatomical pathology business and to lesser extent productivity improvement net of inflationary cost increase these increase were offset in part by strategic growth investment sale mix and unfavorable foreign currency exchange the company reference to strategic growth investment generally refer to targeted spending for enhancing commercial capability including expansion of geographic sale reach and commerce platform marketing initiative expanded service and operational infrastructure focused research project and other expenditure to enhance the customer experience the company reference throughout this discussion to productivity improvement generally refer to improved cost efficiency from it practical process improvement ppi business system reduced cost resulting from global sourcing initiative lower cost structure following restructuring action including headcount reduction and consolidation of facility and low cost region manufacturing the company recorded million provision for income tax in including million related to the gain on the sale of the anatomical pathology business in the company recorded million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and recorded million income tax benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable the company recorded million provision for income tax in including net provision of million to adjust the estimated initial effect of the tax cut and job act of the tax act recorded in consisting of an incremental provision of million offset in part by million reduction of related unrecognized tax benefit established in these adjustment were required based on new treasury guidance and further analysis of available tax accounting method and election legislative update regulation earnings and profit computation and foreign tax in the provision for income tax also included million charge to establish valuation allowance against net operating loss that will not be utilized result of the sale of the anatomical pathology business the effective tax rate in both and wa also affected by relatively significant earnings in lower tax jurisdiction due primarily to the non deductibility of intangible asset amortization for tax purpose the company cash payment for income tax were higher than it income tax expense for financial reporting purpose and totaled million and million in and respectively the company expects it effective tax rate in will be between and based on currently forecasted rate of profitability in the country in which the company conduct business and expected generation of foreign tax credit the effective tax rate can vary significantly from period to period result of discrete income tax factor and event income from continuing operation increased to billion in from billion in principally due to increase in operating income in discussed above offset in part by million of loss on the early extinguishment of debt in note during the company cash flow from operation totaled billion compared with billion for the increase primarily resulted from higher income before amortization and depreciation and lower investment in working capital in the period of december the company short term debt totaled million including million of senior note due within the next twelve month the company ha revolving credit facility with bank group that provides up to billion of unsecured multi currency revolving credit if the company borrows under this facility it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide source of fund in the event that commercial paper market are not available of december no borrowing were outstanding under the company revolving credit facility although available capacity wa reduced by approximately million result of outstanding letter of credit the company belief that it existing cash and cash equivalent of billion of december and it future cash flow from operation together with available borrowing capacity under it revolving credit agreement will be sufficient to meet the cash requirement of it existing business for the foreseeable future including at least the next month fisher scientific inc management discussion and analysis of financial condition and result of operation critical accounting policy and estimatesthe company discussion and analysis of it financial condition and result of operation is based upon it financial statement which have been prepared in accordance with accounting principle generally accepted in the united state of america the preparation of these financial statement requires management to make estimate and assumption that affect the reported amount of asset liability revenue and expense and related disclosure of contingent liability on an on going basis management evaluates it estimate including those related to intangible asset and goodwill income tax and contingency and litigation management belief the most complex and sensitive judgment because of their significance to the consolidated financial statement result primarily from the need to make estimate about the effect of matter that are inherently uncertain management base it estimate on historical experience current market and economic condition and other assumption that management belief are reasonable the result of these estimate form the basis for judgment about the carrying value of asset and liability where the value are not readily apparent from other source actual result may differ from these estimate under different assumption or condition the company belief the following represent it critical accounting policy and estimate used in the preparation of it financial statement intangible asset and goodwillthe company us assumption and estimate in determining the fair value of asset acquired and liability assumed in business combination the determination of the fair value of intangible asset which represent significant portion of the purchase price in many of the company acquisition requires the use of significant judgment with regard to the fair value and ii whether such intangible are amortizable or non amortizable and if the former the period and the method by which the intangible asset will be amortized the company estimate the fair value of acquisition related intangible asset principally based on projection of cash flow that will arise from identifiable intangible asset of acquired business the projected cash flow are discounted to determine the present value of the asset at the date of acquisition definite lived intangible asset totaled billion at december the company review definite lived intangible asset for impairment when indication of potential impairment exists such significant reduction in cash flow associated with the asset actual cash flow arising from particular intangible asset could vary from projected cash flow which could imply different carrying value from those established at the date of acquisition and which could result in impairment of such asset the company evaluates goodwill and indefinite lived intangible asset for impairment annually and when event occur or circumstance change that would more likely than not reduce the fair value of the asset below it carrying amount event or circumstance that might require an interim evaluation include unexpected adverse business condition economic factor unanticipated technological change or competitive activity loss of key personnel and act by government and court goodwill and indefinite lived intangible asset totaled billion and billion respectively at december estimate of discounted future cash flow require assumption related to revenue and operating income growth rate discount rate and other factor for the goodwill impairment test the company considers peer revenue and earnings trading multiple from company that have operational and financial characteristic that are similar to the respective reporting unit and ii estimated weighted average cost of capital different assumption from those made in the company analysis could materially affect projected cash flow and the company evaluation of goodwill and indefinite lived intangible asset for impairment for reporting unit where the company performed the quantitative goodwill impairment test indication of fair value based on projection of profitability and on peer revenue and earnings trading multiple were sufficient to conclude that no impairment of goodwill or indefinite lived intangible asset existed at the end of the tenth fiscal month of the date of the company annual impairment testing there can be no assurance however that an economic downturn will not materially adversely affect peer trading multiple and the company business such that they do not achieve their forecasted profitability and these asset become impaired should the fair value of the company goodwill or indefinite lived intangible asset decline because of reduced operating performance market decline or other indicator of impairment or result of change in the discount rate charge for impairment may be necessary income taxesin the ordinary course of business there is inherent uncertainty in quantifying the company income tax position the company ass income tax position and record tax benefit for all year subject to examination based upon management evaluation of the fact circumstance and information available at the reporting date for those tax fisher scientific inc management discussion and analysis of financial condition and result of operationscritical accounting policy and estimate continued position where it is more likely than not that tax benefit will be sustained the company ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement should tax return position that the company expects are sustainable not be sustained upon audit the company could be required to record an incremental tax provision for such tax the company liability for these unrecognized tax benefit totaled billion at december the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires the company to interpret the related tax law and regulation and the use of estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit change in tax law regulation agreement and treaty currency exchange restriction or the company level of operation or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balance and hence the company net income the company estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which the company ha been able to determine that it deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used the company revers the related valuation allowance any such reversal are recorded reduction of the company tax provision the company tax valuation allowance totaled million at december should the company actual future taxable income by tax jurisdiction vary from estimate additional allowance or reversal thereof may be necessary the company ha not provided state income tax or additional non tax on certain of it non subsidiary undistributed earnings such amount are intended to be reinvested outside the united state indefinitely in the respective jurisdiction based on specific business plan and tax strategy these business plan and tax strategy consider short term and long term forecast and budget of the parent and non subsidiary working capital and other need in location where earnings are generated the company past practice regarding non subsidiary dividend source of financing by the parent such issuing debt or equity and us of cash by the parent that are more discretionary in nature such business combination and share repurchase program however should the company change it business plan and tax strategy in the future and decide to repatriate portion of these earnings to one of it subsidiary including cash maintained by these non subsidiary the company would recognize additional tax liability it is not practicable to estimate the amount of additional state income tax and non tax liability that the company would incur the company intent is to only make distribution from non subsidiary in the future when they can be made at no net tax cost contingency and litigationthe company record accrual for various contingency including legal proceeding environmental worker compensation product general and auto liability and other claim that arise in the normal course of business the accrual are based on management judgment historical claim experience the probability of loss and where applicable the consideration of opinion of internal and or external legal counsel and actuarial estimate accrual of acquired business including product liability and environmental accrual are initially recorded at fair value and discounted to their net present value additionally the company record receivables from third party insurer when recovery ha been determined to be probable fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of compared with in million other acquisition divestituresoperationsrevenues life science solution analytical specialty laboratory product and elimination consolidated revenue currency translation other for the laboratory product and service segment includes reduction of revenue of million for the impact of change in the method of reporting certain intersegment sale with no impact on consolidated result sale in were billion an increase of billion from sale increased million due to acquisition the unfavorable effect of currency translation resulted in decrease in revenue of million in aside from the effect of acquisition and currency translation revenue increased billion primarily due to increased demand sale to customer in each of the company primary end market grew with particular strength in sale to customer in the biotech and pharmaceutical industry sale growth wa strong in each of the company primary geographic area in in the fourth quarter of sale to industrial customer declined and sale growth in asia wa modest due to weaker end market condition off of strong fourth quarter in in total company operating income and operating income margin were billion and respectively compared with billion and respectively in the increase in operating income wa primarily due to profit on higher sale the gain on the sale of the anatomical pathology business and to lesser extent productivity improvement net of inflationary cost increase these increase were offset in part by strategic growth investment sale mix and unfavorable foreign currency exchange in the company recorded restructuring and other income net of million including million of net gain on the sale of business principally the anatomical pathology business see note the company also recorded million of charge to cost of revenue primarily for the sale of inventory revalued at the date of acquisition and million of net charge to selling general and administrative expense principally transaction and integration related cost related to acquisition and divestiture in addition the company recorded million of cash restructuring charge net primarily for employee severance and abandoned facility cost associated with the closure and consolidation of facility in the and europe see note in the company recorded restructuring and other cost net of million including million of charge to cost of revenue primarily for the sale of inventory revalued at the date of acquisition the company recorded million of net charge to selling general and administrative expense primarily for third party transaction and integration cost associated with recent and pending acquisition offset in part by income from favorable result of product liability litigation in addition the company recorded million of cash restructuring cost in it continued effort to streamline operation including severance at several business and abandoned facility expense at business that have been or are being consolidated in the and europe the company also recorded million of other income net principally for resolution of litigation matter of february the company ha identified restructuring action that will result in additional charge of approximately million primarily in and expects to identify additional action during which will be recorded when specified criterion are met such communication of benefit arrangement or when the cost have been incurred approximately of the additional charge will be incurred in the life science solution segment in the analytical instrument segment in the laboratory product and service segment and in the specialty diagnostics segment the restructuring project for which charge were incurred in are expected to result in annual cost saving of approximately million beginning in part in and to greater extent in including million in the life science solution segment million in the analytical instrument segment million in the specialty diagnostics segment and fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued million in the laboratory product and service segment the restructuring action for which charge were incurred in resulted in annual cost saving of approximately million beginning in part in and to greater extent in including million in the life science solution segment million in the analytical instrument segment million in the specialty diagnostics segment and million in the laboratory product and service segment segment resultsthe company management evaluates segment operating performance using operating income before certain charge credit to cost of revenue and selling general and administrative expense principally associated with acquisition related activity restructuring and other cost income including cost arising from facility consolidation such severance and abandoned lease expense and gain and loss from the sale of real estate and product line and amortization of acquisition related intangible asset the company us this measure because it help management understand and evaluate the segment core operating result and facilitate comparison of performance for determining compensation note accordingly the following segment data is reported on this basis dollar in million science solution analytical specialty laboratory product and elimination consolidated revenue segment incomelife science solution analytical specialty laboratory product and subtotal reportable cost of revenue charge selling general and administrative charge net restructuring and other cost income amortization of acquisition related intangible asset consolidated operating income reportable segment operating income consolidated operating income income from the company reportable segment increased to billion in due primarily to profit on higher sale and to lesser extent productivity improvement net of inflationary cost increase offset in part by strategic growth investment sale mix and unfavorable foreign currency exchange life science solution dollar in million operating income fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued sale in the life science solution segment increased million to billion in sale increased million due to higher revenue at existing business and million due to an acquisition the unfavorable effect of currency translation resulted in decrease in revenue of million the increase in revenue at existing business wa primarily due to increased demand in each of the segment principal business with particular strength in sale of bioproduction and bioscience product operating income margin wa in compared to in the increase in operating margin resulted primarily from profit on higher sale offset in part by strategic growth investment and to lesser extent sale mix and unfavorable foreign currency exchange analytical instrument dollar in million operating income ptsales in the analytical instrument segment increased million to billion in sale increased million due to higher revenue at existing business the unfavorable effect of currency translation resulted in decrease in revenue of million the increase in revenue at existing business wa due to increased demand for product sold by each of the segment primary business with particular strength in chromatography and mass spectrometry instrument sale decreased in the fourth quarter of due to industrial end market condition off of strong fourth quarter of operating income margin wa in compared to in the increase resulted primarily from profit on higher sale and productivity improvement net of inflationary cost increase these increase were offset in part by sale mix and strategic growth investment specialty diagnostics dollar in million operating income ptsales in the specialty diagnostics segment remained flat at billion in sale increased million due to higher revenue at existing business the unfavorable effect of currency translation resulted in decrease in revenue of million and the divestiture of the anatomical pathology business decreased revenue by million the increase in revenue at existing business wa due to increased demand for product sold through the segment healthcare market channel well clinical diagnostic and immunodiagnostic product operating income margin wa in and in the decrease wa primarily due to strategic growth investment and to lesser extent sale mix and the divestiture of the anatomical pathology business these decrease were offset in part by profit on higher sale and to lesser extent productivity improvement net of inflationary cost increase following multi year extension of several expiring licensing arrangement with commercial partner segment revenue and operating income in will both be unfavorably affected by approximately million laboratory product and service dollar in million operating income ptsales in the laboratory product and service segment increased million to billion in sale increased million due to higher revenue at existing business and million due to acquisition the unfavorable effect of currency translation resulted in decrease in revenue of million change in the method of reporting certain intersegment sale reduced segment revenue by million with no impact to consolidated result the increase in revenue at fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued existing business wa primarily due to increased demand in each of the segment principal business with particular strength in service offering of it pharma service business and product sold through it research and safety market channel business operating income margin wa in both and increase from profit on higher sale and productivity improvement net of inflationary cost increase were offset by strategic growth investment and to lesser extent sale mix other expense income netin the company recorded million of loss on the early extinguishment of debt offset in part by million of net gain on investment the investment gain include million gain on the sale of joint venture for net proceeds of million in the company recorded million of net loss on investment provision for income taxesthe company recorded million provision for income tax in including million related to the gain on the sale of the anatomical pathology business in the company recorded million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and recorded million income tax benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable the company recorded million provision for income tax in including net provision of million to adjust the estimated initial effect of the tax cut and job act of recorded in consisting of an incremental provision of million offset in part by million reduction of related unrecognized tax benefit established in these adjustment were required based on new treasury guidance and further analysis of available tax accounting method and election legislative update regulation earnings and profit computation and foreign tax in the provision for income tax also included million charge to establish valuation allowance against net operating loss that will not be utilized result of the sale of the anatomical pathology business the effective tax rate in both and wa also affected by relatively significant earnings in lower tax jurisdiction due primarily to the non deductibility of intangible asset amortization for tax purpose the company cash payment for income tax were higher than it income tax expense for financial reporting purpose and totaled million and million in and respectively the company expects it effective tax rate in will be between and based on currently forecasted rate of profitability in the country in which the company conduct business and expected generation of foreign tax credit the effective tax rate can vary significantly from period to period result of discrete income tax factor and event the company ha operation and taxable presence in approximately country outside the some of these country have lower tax rate than the the company ability to obtain benefit from lower tax rate outside the is dependent on it relative level of income in country outside the and on the statutory tax rate in those country based on the dispersion of the company non income tax provision among many country the company belief that change in the statutory tax rate in any individual country is not likely to materially affect the company income tax provision or net income aside from any resulting one time adjustment to the company deferred tax balance to reflect new rate recent accounting pronouncementsa description of recently issued accounting standard is included under the heading recent accounting pronouncement in note contingent liabilitiesthe company is contingently liable with respect to certain legal proceeding and related matter an unfavorable outcome that differs materially from current accrual estimate if any for one or more of the matter described under the heading product liability worker compensation and other personal injury matter and intellectual property matter in note could have material adverse effect on the company financial position well it result of operation and cash flow fisher scientific inc management discussion and analysis of financial condition and result of operationsliquidity and capital resourcesconsolidated working capital current asset le current liability wa billion at december compared with billion at december primarily due to lower short term debt and higher cash balance included in working capital were cash and cash equivalent of billion at december and billion at december cash provided by operating activity wa billion during cash provided by income wa offset in part by increased investment in working capital increase in account receivable and inventory used cash of million and million respectively primarily to support growth in sale an increase in other asset used cash of million primarily due to the timing of customer billing and tax refund other liability increased by million primarily due to advance payment from customer cash payment for income tax increased to million during compared with million in the company made cash contribution to it pension and postretirement benefit plan totaling million during payment for restructuring action principally severance cost and lease and other expense of real estate consolidation used cash of million during during the company investing activity used billion of cash acquisition used cash of billion proceeds from the sale of the anatomical pathology business provided billion the company investing activity also included the purchase of million of property plant and equipment the company financing activity used billion of cash during repayment of senior note used cash of billion new long term borrowing provided cash of billion net decrease in commercial paper obligation used cash of million the company financing activity also included the repurchase of billion of the company common stock and the payment of million in cash dividend offset in part by million of net proceeds from employee stock option exercise on november the board of director replaced the existing authorization to repurchase the company common stock of which million wa remaining with new authorization to repurchase up to billion of the company common stock at february authorization remained for billion of future repurchase of the company common stock of december the company short term debt totaled million including million of senior note due within the next twelve month the company ha revolving credit facility with bank group that provides up to billion of unsecured multi currency revolving credit if the company borrows under this facility it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide source of fund in the event that commercial paper market are not available of december no borrowing were outstanding under the company revolving credit facility although available capacity wa reduced by approximately million result of outstanding letter of credit approximately half of the company cash balance and cash flow from operation are from outside the the company us it non cash for need outside of the including acquisition and repayment of acquisition related intercompany debt to the in addition the company also transfer cash to the using non taxable return of capital well dividend where the related dividend received deduction or foreign tax credit equal any tax cost arising from the dividend result of using such mean of transferring cash to the the company doe not expect any material adverse liquidity effect from it significant non cash balance for the foreseeable future the company belief that it existing cash and cash equivalent of billion of december and it future cash flow from operation together with available borrowing capacity under it revolving credit agreement will be sufficient to meet the cash requirement of it existing business for the foreseeable future including at least the next month cash provided by operating activity wa billion during cash provided by income wa offset in part by investment in working capital increase in account receivable and inventory used cash of million and million respectively primarily to support growth in sale cash payment for income tax increased to million during compared with million in the company made cash contribution to it pension and postretirement benefit plan totaling million during payment for restructuring action principally severance cost and lease and other expense of real estate consolidation used cash of million during during the company investing activity used billion of cash acquisition used cash of million the company investing activity also included the purchase of million of property plant and equipment fisher scientific inc management discussion and analysis of financial condition and result of operationsliquidity and capital resource continued the company financing activity used billion of cash during repayment of senior note used cash of billion new long term borrowing provided cash of million net decrease in commercial paper obligation used cash of million the company financing activity also included the repurchase of million of the company common stock and the payment of million in cash dividend offset in part by million of net proceeds from employee stock option exercise off balance sheet arrangementsthe company not use special purpose entity or other off balance sheet financing arrangement in or except for letter of credit bank guarantee residual value guarantee under three lease agreement surety bond and other guarantee disclosed in the table or discussed below the amount disclosed in the table below for letter of credit bank guarantee surety bond and other guarantee relate to guarantee of the company performance primarily in the ordinary course of business contractual obligation and other commercial commitmentsthe table below summarizes by period due or expiration of commitment the company contractual obligation and other commercial commitment of december payment due by period or expiration of commitment in million and and and thereaftertotalcontractual obligation and other commercial commitment debt principal including short term debt finance lease operating lease unconditional purchase obligation letter of credit and bank surety bond and other pension obligation on balance asset retirement obligation accrued on balance acquisition related contingent consideration accrued on balance amount represent the expected cash payment for debt and do not include any deferred issuance cost unconditional purchase obligation include agreement to purchase good service or fixed asset that are enforceable and legally binding and that specify all significant term including fixed or minimum quantity to be purchased fixed minimum or variable price provision and the approximate timing of the transaction purchase obligation exclude agreement that are cancelable at any time without penalty reserve for unrecognized tax benefit of billion have not been included in the above table due to the inability to predict the timing of tax audit resolution the company ha no material commitment for purchase of property plant and equipment other than those included in the above table but expects that for such expenditure will be between and billion guarantee of residual value under lease arrangement for three facility have not been included in the above table due to the inability to predict if and when the guarantee may require payment see note the residual value guarantee become operative at the end of the lease for up to maximum of million the term of these lease end in and guarantee of pension plan obligation of divested business ha not been included in the preceding table due to the inability to predict if and when the guarantee may require payment the purchaser of the divested business ha agreed to pay for the pension benefit however the company wa required to guarantee payment of these pension benefit should the purchaser fail to do so the amount of the guarantee at december wa million fisher scientific inc management discussion and analysis of financial condition and result of operationsliquidity and capital resource continued in disposing of asset or business the company often provides representation warranty and or indemnity to cover various risk including for example unknown damage to the asset environmental risk involved in the sale of real estate liability to investigate and remediate environmental contamination at waste facility and unidentified tax liability and related legal fee the company doe not have the ability to estimate the potential liability from such indemnity because they relate to unknown condition however the company ha no reason to believe that these uncertainty would have material adverse effect on it financial position annual result of operation or cash flow the company ha recorded liability for known indemnification included part of environmental liability see item business environmental matter for discussion of these liability item quantitative and qualitative disclosure about market riskthe company is exposed to market risk from change in interest rate and currency exchange rate which could affect it future result of operation and financial condition the company manages it exposure to these risk through it regular operating and financing activity the company ha periodically hedged interest rate risk of fixed rate instrument with offsetting interest rate swap additionally the company us short term forward and option contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate such exposure result from purchase sale cash and intercompany loan that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in swiss franc euro canadian dollar swedish kronor british pound sterling japanese yen and czech koruna income and loss arising from these derivative contract are recognized offset to loss and income resulting from the underlying exposure being hedged the company doe not enter into speculative derivative agreement interest ratesthe company is exposed to change in interest rate while conducting normal business operation result of ongoing investing and financing activity which affect the company debt well cash and cash equivalent of december the company debt portfolio wa comprised primarily of fixed rate borrowing the fair market value of the company fixed interest rate debt is subject to interest rate risk generally the fair market value of fixed interest rate debt will increase interest rate fall and decrease interest rate rise the total estimated fair value of the company debt at december wa billion see note fair value were determined from available market price using current interest rate and term to maturity if interest rate were to decrease by basis point the fair value of the company debt at december would increase by approximately billion if interest rate were to increase by basis point the fair value of the company debt at december would decrease by approximately billion in addition interest rate change would result in change in the company interest expense due to variable rate debt instrument including swap arrangement in basis point increase in interest rate on the swap arrangement and variable rate debt would have increased the company annual pre tax interest expense by approximately million currency exchange ratesthe company view it investment in international subsidiary with functional currency other than the dollar permanent the company investment in international subsidiary is sensitive to fluctuation in currency exchange rate the functional currency of the company international subsidiary are principally denominated in british pound sterling swedish kronor euro canadian dollar swiss franc norwegian krone and danish krone the effect of change in the period ending currency exchange rate on the company net investment in international subsidiary is reflected in the accumulated other comprehensive item component of shareholder equity the company also us foreign currency denominated debt to partially hedge it net investment in foreign operation against adverse movement in exchange rate depreciation in year end functional currency relative to the dollar would result in reduction of shareholder equity of billion the fair value of forward currency exchange contract is sensitive to change in currency exchange rate the fair value of forward currency exchange contract is the estimated amount that the company would pay or receive upon termination of the contract taking into account the change in currency exchange rate depreciation in year end non functional currency exchange rate related to the company contract would result in an additional unrealized loss on forward currency exchange contract of million appreciation in year end non functional currency exchange rate related to the company contract would result in an unrealized gain on forward currency exchange contract of million the fisher scientific inc quantitative and qualitative disclosure about market risk continued unrealized gain or loss on forward currency exchange contract resulting from change in currency exchange rate are expected to approximately offset loss or gain on the exposure being hedged certain of the company cash and cash equivalent are denominated in currency other than the functional currency of the depositor and are sensitive to change in currency exchange rate depreciation in the related year end non functional currency exchange rate applied to such cash balance would result in negative impact of million on the company net income item financial statement and supplementary datathis data is submitted separate section to this report see item exhibit and financial statement schedule item change in and disagreement with accountant on accounting and financial disclosurenot applicable item control and proceduresmanagement evaluation of disclosure control and proceduresthe company management with the participation of the company chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure such term is defined in rule and under the exchange act of the end of the period covered by this report based on such evaluation the company chief executive officer and chief financial officer concluded that of the end of such period the company disclosure control and procedure were effective at the reasonable assurance level change in internal control over financial reportingthere have been no change in the company internal control over financial reporting defined in exchange act rule and during the fiscal quarter ended december that have materially affected or are reasonably likely to materially affect the company internal control over financial reporting management annual report on internal control over financial reportingthe company management including the company chief executive officer and chief financial officer is responsible for establishing and maintaining adequate internal control over financial reporting defined in exchange act rule and for the company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle the company management conducted an assessment of the effectiveness of the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso based on this assessment the company management concluded that of december the company internal control over financial reporting wa effective the company independent registered public accounting firm pricewaterhousecoopers llp ha audited the effectiveness of the company internal control over financial reporting of december stated in their report that appears on page of this annual report on form item other informationnot applicable fisher scientific inc part iiiitem director executive officer and corporate governancethe information with respect to director required by this item will be contained in our definitive proxy statement to be filed with the sec not later than day after the close of business of the fiscal year definitive proxy statement and is incorporated in this report by reference the information with respect to executive officer required by this item is included in item of part of this report the other information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item executive compensationthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item security ownership of certain beneficial owner and management and related stockholder mattersthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item certain relationship and related transaction and director independencethe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item principal accountant fee and servicesthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference part ivitem exhibit and financial statement schedule the following document are filed part of this report consolidated financial statement see index on page of this report report of independent registered public accounting firmconsolidated balance sheetconsolidated statement of incomeconsolidated statement of comprehensive incomeconsolidated statement of cash flowsconsolidated statement of shareholder equitynotes to consolidated financial statement all schedule are omitted because they are not applicable or not required or because the required information is included either in the consolidated financial statement or in the note thereto exhibitssee the exhibit index on page item form summarynone to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized date february fisher scientific inc by marc caspermarc casperchairman president and chief executive officerpursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity indicated of february by marc casperby jim manzimarc casperjim manzichairman president and chief executive officerdirector principal executive officer by stephen williamsonby james mullenstephen williamsonjames mullensenior vice president and chief financial officerdirector principal financial officer by lars srensenby peter hornstralars srensenpeter hornstradirectorvice president and chief accounting officer principal accounting officer by debora sparby nelson chaidebora sparnelson chaidirectordirectorby martin harrisby scott sperlingc martin harrisscott sperlingdirectordirectorby tyler jacksby elaine ulliantyler jackselaine ulliandirectordirectorby judy lewentby dion weislerjudy lewentdion weislerdirectordirectorby thomas lynchthomas fisher scientific inc exhibit indexexhibit numberdescription of and restated certificate of incorporation of the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference to thermo fisher scientific inc third amended and restated certificate of incorporation filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference of elimination of the series junior participating preferred stock of the company dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference law of the registrant amended and effective of march filed exhibit to the registrant current report on form filed march file no and incorporated in this document by reference the registrant agrees pursuant to item iii of regulation to furnish to the commission upon request copy of each instrument with respect to long term debt of the registrant or it consolidated subsidiary dated of november between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of december between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference supplemental indenture dated of november among the company the bank of new york mellon trust company trustee and the bank of new york mellon london branch paying agent filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of july among the company the bank of new york mellon trust company trustee and the bank of new york mellon london branch paying agent filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference supplemental indenture dated of december between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference supplemental indenture dated of april between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed april file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of march between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed march file no and incorporated in this document by reference supplemental indenture dated of july between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference supplemental indenture dated of august between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference supplemental indenture dated of september between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of october between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference dated of august among thermo fisher scientific finance issuer the company guarantor and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference supplemental indenture dated of august among thermo fisher scientific finance issuer the company guarantor and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of the registrant security fisher scientific inc deferred compensation plan for director of the registrant amended and restated on september filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference electron corporation deferred compensation plan effective november filed exhibit to the registrant annual report on form for the fiscal year ended december file no and incorporated in this document by reference of amended and restated indemnification agreement between the registrant and it director and officer filed exhibit to the registrant registration statement on form reg no and incorporated in this document by reference of thermo fisher scientific inc annual director compensation of annual cash incentive plan matter set forth in item to the registrant current report on form filed february file no under the heading compensatory arrangement of certain officer and incorporated in this document by reference of noncompetition agreement between the registrant and certain key employee and executive officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc annual report on form for the year ended december file no and incorporated in this document by reference amendment to the fisher scientific international inc retirement plan for non employee director filed exhibit to fisher scientific international inc quarterly report on form for the quarter ended march file no and incorporated in this document by reference to retirement plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc current report on form filed march file no and incorporated in this document by reference fisher scientific inc amended and restated deferred compensation plan effective january filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc stock incentive plan filed exhibit to the registrant current report on form filed may file no and incorporated in this document by reference no to thermo fisher scientific inc amended and restated deferred compensation plan filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference restatement of executive severance agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference change in control retention agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference no to restatement of executive severance agreement dated february between the registrant and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference no to restatement of executive severance agreement dated november between the registrant and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated november between marc casper and the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated march between marc casper and the registrant filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of executive change in control retention agreement for officer other than marc casper filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference to stock incentive plan dated november filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of thermo fisher scientific inc restricted stock unit agreement for director filed exhibit to the registrant quarterly report on form for the quarter ended april file no and incorporated in this document by reference of thermo fisher scientific inc performance restricted stock unit agreement filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of stock option agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference fisher scientific inc stock incentive plan filed exhibit to the registrant current report on form filed may file no and incorporated in this document by reference executive retirement plan effective of december amended and restated of august filed exhibit to applera corporation quarterly report on form for the quarter ended september file no and incorporated in this document by reference to supplemental executive retirement plan effective of january filed exhibit to life technology corporation current report on form filed december file no and incorporated in this document by reference agreement between the registrant and mark stevenson dated september filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference of thermo fisher scientific inc stock option agreement for officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference omnibus incentive plan filed exhibit to the current report on form filed by patheon on july file no and incorporated in this document by reference to patheon omnibus incentive plan dated march filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference to patheon omnibus incentive plan dated august filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference agreement dated july among the company certain subsidiary of the company from time to time party thereto each lender from time to time party thereto and bank of america filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference of performance restricted stock unit agreement effective february filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of performance restricted stock unit agreement for marc casper effective february filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference agreement between the registrant and michel lagarde dated august agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated july share unit award agreement between patheon and michel lagarde dated march amended agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated march fisher scientific inc executive severance policy filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference of noncompetition agreement between the registrant and certain key employee and executive officer filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of thermo fisher scientific inc performance restricted stock unit agreement of thermo fisher scientific inc restricted stock unit agreement of thermo fisher scientific inc stock option agreement for officer of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper of restricted stock unit agreement between thermo fisher scientific inc and marc casper of stock option agreement between thermo fisher scientific inc and marc casper of the registrant of pricewaterhousecoopers llp an independent registered public accounting firm of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of insxbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document schxbrl taxonomy extension schema document calxbrl taxonomy calculation linkbase document defxbrl taxonomy definition linkbase document labxbrl taxonomy label linkbase document prexbrl taxonomy presentation linkbase document page interactive data file formatted inline xbrl and contained in exhibit _______________________ indicates management contract or compensatory plan contract or arrangement certification is not deemed filed for purpose of section of the exchange act or otherwise subject to the liability of that section such certification is not deemed to be incorporated by reference into any filing under the security act or the exchange act except to the extent that the registrant specifically incorporates it by reference fisher scientific inc index of consolidated financial statement the following consolidated financial statement of the registrant and it subsidiary are required to be included in item page report of independent registered public accounting firmf balance sheet of december and statement of income for the year ended december and statement of comprehensive income for the year ended december and statement of cash flow for the year ended december and statement of shareholder equity for the year ended december and to consolidated financial statementsf of independent registered public accounting firmto the board of director and shareholder of thermo fisher scientific inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of thermo fisher scientific inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of shareholder equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement we also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in our opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso change in accounting principleas discussed in note to the consolidated financial statement the company changed the manner in which it account for lease in basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management annual report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the consolidated financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate goodwill impairment assessmentas described in note to the consolidated financial statement the company consolidated goodwill balance wa million of december management evaluates goodwill impairment at the reporting unit level annually and when event occur or circumstance change that would more likely than not reduce the fair value of the reporting unit below it carrying amount in performing the assessment management estimate the fair value of it reporting unit by using forecast of discounted future cash flow and peer market multiple disclosed by management estimate of discounted future cash flow require management to make assumption related to revenue and operating income growth rate discount rate and other factor management also considers peer revenue and earnings trading multiple from company that have operational and financial characteristic that are similar to the respective reporting unit and estimate weighted average cost of capital the principal consideration for our determination that performing procedure relating to the goodwill impairment assessment is critical audit matter are there wa significant judgment by management when estimating the fair value of the reporting unit this in turn led to high degree of auditor judgment subjectivity and effort in performing procedure to evaluate management cash flow projection and significant assumption including revenue and operating income growth rate discount rate and peer market multiple in addition the audit involved the use of professional with specialized skill and knowledge to assist in performing these procedure and evaluating the audit evidence obtained from these procedure addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to the goodwill impairment assessment including control over the development of assumption used by management to estimate the fair value of the company reporting unit these procedure also included among others testing management process for developing the fair value estimate evaluating the appropriateness of the discounted cash flow model testing the completeness accuracy and relevance of underlying data used in the model and evaluating the reasonableness of the assumption used including revenue and operating income growth rate discount rate and peer market multiple evaluating the reasonableness of management assumption related to revenue and operating income growth rate involved evaluating whether the assumption used were reasonable considering the current and past performance of the reporting unit and ii whether the assumption were consistent with evidence obtained in other area of the audit evaluating the reasonableness of the peer market multiple assumption involved evaluating the population of peer company used in the analysis and testing selected market data used by management to determine the multiple by comparison to publicly available information professional with specialized skill and knowledge were used to assist in evaluating the appropriateness of the company discounted cash flow model and certain significant assumption including the discount rate income taxesas described in note and to the consolidated financial statement the company total income tax expense for the period ended december wa million the company ha deferred income tax liability net of million including valuation allowance of million and unrecognized income tax benefit of million of december disclosed by management the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires management to interpret the related tax law and regulation and use estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit management ass income tax position and record tax benefit for all year subject to examination based upon evaluation of the fact circumstance and information available at the reporting date for those tax position where it is more likely than not that tax benefit will be sustained management ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement management estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which management ha been able to determine that the company deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used management revers the related valuation allowance the principal consideration for our determination that performing procedure relating to income tax is critical audit matter are there wa significant judgment by management when determining the provision for income tax deferred tax asset and liability and liability for unrecognized tax benefit due to numerous and complex tax law the frequency of tax filing well judgment regarding the realizability of deferred tax asset this in turn led to high degree of auditor judgment subjectivity and effort in performing procedure and evaluating audit evidence related to the provision for income tax deferred tax asset and liability and for unrecognized tax benefit in addition the audit effort involved the use of professional with specialized skill and knowledge to assist in performing these procedure and evaluating the audit evidence obtained from these procedure addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the financial statement these procedure included testing the effectiveness of control relating to the provision for income tax deferred tax asset and liability and liability for unrecognized tax benefit including control over management assessment of the realizability of deferred tax asset these procedure also included among others testing the accuracy of the income tax provision including the rate reconciliation and permanent and temporary difference ii evaluating whether the data utilized in the calculation of the provision for income tax wa appropriate and consistent with evidence obtained in other area of the audit iii evaluating management assessment of the realizability of deferred tax asset on jurisdictional basis iv evaluating the identification of reserve for unrecognized tax benefit and the reasonableness of the more likely than not determination in consideration of jurisdiction court decision legislative action statute of limitation and development in tax examination testing the calculation of the liability for unrecognized tax benefit by jurisdiction including estimate of the amount of tax benefit expected to be sustained and vi evaluating the adequacy of the company disclosure professional with specialized skill and knowledge were used to assist in evaluating the reasonableness of management judgment and estimate including application of foreign and domestic tax law and regulation pricewaterhousecoopers llpboston massachusettsfebruary we have served the company auditor since fisher scientific inc consolidated balance sheet december december in million except share and per share amount asset cash and cash equivalent account receivable le allowance of and contract asset other current total current property plant and equipment acquisition related intangible asset other total asset liability and shareholder equitycurrent liability short term obligation and current maturity of long term obligation account accrued payroll and employee contract other accrued total current deferred income other long term long term commitment and contingency note shareholder equity preferred stock par value share authorized none issuedcommon stock par value share authorized and share capital in excess of par retained treasury stock at cost and share accumulated other comprehensive item total shareholder total liability and shareholder equity the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of income year ended december december december in million except per share amount revenue service total cost and operating expense cost of product cost of service selling general and administrative research and development restructuring and other income cost net total cost and operating operating interest interest expense other expense income net income from continuing operation before income provision for income tax income from continuing loss from discontinued operation net of income tax benefit of and net income earnings per share from continuing operationsbasic diluted earnings per sharebasic diluted weighted average the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of comprehensive income year ended december december december in million incomenet income other comprehensive item currency translation adjustment currency translation adjustment net of tax provision benefit of and reclassification adjustment for loss included in net income unrealized gain and loss on available for sale investment unrealized holding loss arising during the period net of tax benefit of and reclassification adjustment for gain included in net income net of tax provision of and unrealized gain and loss on hedging instrument unrealized loss on hedging instrument net of tax benefit of and reclassification adjustment for loss included in net income net of tax benefit of and pension and other postretirement benefit liability adjustment pension and other postretirement benefit liability adjustment arising during the period net of tax benefit provision of and amortization of net loss and prior service benefit included in net periodic pension cost net of tax benefit of and total other comprehensive item comprehensive income the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of cash flowsyear endeddecember december december in million activitiesnet income loss from discontinued operation income from continuing adjustment to reconcile income from continuing operation to net cash provided by operating activity depreciation of property plant and amortization of acquisition related intangible change in deferred income tax gain on sale of business non cash stock based loss on early extinguishment of other non cash expense change in asset and liability excluding the effect of acquisition and disposition account receivable inventory other asset account other contribution to retirement plan net cash provided by continuing net cash used in discontinued operation net cash provided by operating investing activity acquisition net of cash acquired proceeds from sale of business net of cash purchase of property plant and equipment proceeds from sale of property plant and other investing activity net cash used in investing activity financing activitiesnet proceeds from issuance of repayment of debt proceeds from issuance of commercial repayment of commercial paper purchase of company common stock dividend paid net proceeds from issuance of company common stock net proceeds from issuance of company common stock under employee stock other financing activity net net cash used in provided by financing activity exchange rate effect on cash increase in cash cash equivalent and restricted cash cash equivalent and restricted cash at beginning of cash cash equivalent and restricted cash at end of period the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of shareholder equity common stockcapital in excess of par valueretained earningstreasury stockaccumulated other comprehensive itemstotal shareholder equity in million sharesamountsharesamountbalance at december issuance of share under employee and director stock issuance of stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item other balance at december cumulative effect of accounting change issuance of share under employee and director stock stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item other balance at december cumulative effect of accounting change issuance of share under employee and director stock stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item balance at december the accompanying note are an integral part of these consolidated financial statement fisher scientific inc note to consolidated financial statementsnote nature of operation and summary of significant accounting policy nature of operationsthermo fisher scientific inc the company or thermo fisher enables customer to make the world healthier cleaner and safer by helping them accelerate life science research solve complex analytical challenge improve patient diagnostics deliver medicine to market and increase laboratory productivity market served include pharmaceutical and biotech academic and government industrial and applied well healthcare and diagnostics principle of consolidationthe accompanying financial statement include the account of the company and it wholly and majority owned subsidiary all material intercompany account and transaction have been eliminated the company account for investment in business using the equity method when it ha the ability to exercise significant influence but not control generally between and ownership and is not the primary beneficiary presentationcertain reclassification of prior year amount have been made to conform to the current year presentation revenue recognitionprior to the company recognized revenue after all significant obligation had been met collectability wa probable and title had passed which typically occurred upon shipment delivery completion of service or ratably over the contract period beginning in the company recognizes revenue performance obligation are satisfied by transferring control of promised good or service to customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those good or service see recent accounting pronouncement below for discussion of the change in revenue recognition accounting that became effective in consumables revenue consist of single use product and are recognized at point in time following the transfer of control of such product to the customer which generally occurs upon shipment instrument revenue typically consist of longer lived asset that for the substantial majority of sale are recognized at point in time in manner similar to consumables service revenue clinical trial logistics pharmaceutical development and manufacturing service asset management diagnostic testing training service contract and field service including related time and material are recognized over time customer receive and consume the benefit of such service for revenue recognized over time the company generally us cost accumulated relative to total estimated cost to measure progress this method approximates satisfaction of the performance obligation for contract that contain multiple performance obligation the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling price and recognizes the related revenue when or control of each individual performance obligation is transferred to customer the company exercise judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer ha the ability to direct the use of and obtain substantially all of the remaining benefit of the asset the company immediately expense contract cost that would otherwise be capitalized and amortized over period of le than one year payment from customer for most instrument consumables and service are typically due in fixed number of day after shipment or delivery of the product service arrangement commonly call for payment in advance of performing the work extended service contract upon completion of the service pharmaceutical development and manufacturing or mix of both see note for revenue disaggregated by type and by geographic region well further information about remaining performance obligation contract related balancesaccounts receivable include amount that have been billed and are currently due from customer they are recorded at the invoiced amount and do not bear interest the company maintains allowance for doubtful account for estimated loss resulting from the inability of it customer to pay amount due the allowance for doubtful account is the company best estimate of the amount of probable credit loss in existing account receivable the company determines the allowance based on the age of the receivable the creditworthiness of the customer and any other information that is relevant to the judgment account balance are charged off against the allowance when the company belief it is probable the receivable will not be recovered the company doe not have any off balance sheet credit exposure related to customer fisher scientific inc note to consolidated financial statement continued the change in the allowance for doubtful account are follows year ended december in million balance provision charged to account written off acquisition currency translation and other ending balance contract asset include revenue recognized in advance of billing and are recorded net of estimated loss resulting from the inability to invoice customer contract asset are classified current or noncurrent based on the amount of time expected to lapse the company right to consideration becomes unconditional noncurrent contract asset are included within other asset in the accompanying balance sheet contract liability include billing in excess of revenue recognized such those resulting from customer advance and deposit and unearned revenue on service contract contract liability are classified current or noncurrent based on the period over which remaining performance obligation are expected to be transferred to customer noncurrent contract liability are included within other long term liability in the accompanying balance sheet contract asset and liability are presented on net basis in the consolidated balance sheet if they arise from different performance obligation in the contract contract asset and liability balance are follows december december in million contract asset net noncurrent contract asset current contract noncurrent contract substantially all of the current contract liability balance at december and january wa recognized in revenue during and respectively contract asset increased in primarily due to growth in pharmaceutical development and manufacturing service contract liability increased during primarily due to an advance payment from customer and an acquisition warranty obligationsthe company provides for the estimated cost of standard product warranty primarily from historical information in cost of product revenue at the time product revenue is recognized while the company engages in extensive product quality program and process including actively monitoring and evaluating the quality of it component supply the company warranty obligation is affected by product failure rate utilization level material usage service delivery cost incurred in correcting product failure and supplier warranty on part delivered to the company should actual product failure rate utilization level material usage service delivery cost or supplier warranty on part differ from the company estimate revision to the estimated warranty liability would be required the liability for warranty is included in other accrued expense in the accompanying balance sheet extended warranty agreement are considered service contract which are discussed above cost of service contract are recognized incurred the change in the carrying amount of standard product warranty obligation are follows fisher scientific inc note to consolidated financial statement continued year ended december december in million balance provision charged to usage adjustment to previously provided warranty net currency translation ending balance leasesthe company determines whether an arrangement is or contains lease at inception prior to the company did not account for operating lease on the balance sheet beginning in discussed below under recent accounting pronouncement operating lease that have commenced are included in other asset other accrued expense and other long term liability in the consolidated balance sheet classification of operating lease liability either current or noncurrent is based on the expected timing of payment due under the company obligation right of use rou asset represent the company right to use an underlying asset for the lease term and lease liability represent the company obligation to make lease payment arising from the lease operating lease rou asset and liability are recognized at the lease commencement date based on the present value of lease payment over the lease term lease with an initial term of month or le are not recorded on the consolidated balance sheet the company recognizes lease expense for these lease on straight line basis over the lease term because most of the company lease do not provide an implicit rate the company estimate incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payment the company us the implicit rate when readily determinable lease term may include the effect of option to extend or terminate the lease when it is reasonably certain that the company will exercise that option operating lease expense is recognized on straight line basis over the lease term lessee the company account for the lease and non lease component single lease component see note additional information about the company lease research and developmentthe company conduct research and development activity to increase it depth of capability in technology software and service research and development cost include employee compensation and benefit consultant facility related cost material cost depreciation and travel research and development cost are expensed incurred restructuring costsaccounting for the timing and amount of termination benefit provided by the company to employee is determined based on whether the company ha substantive plan to provide such benefit the company ha written employment contract with the affected employee that includes provision for such benefit the termination benefit are due to the occurrence of an event specified in an existing plan or agreement or the termination benefit are one time benefit in certain circumstance employee termination benefit may meet more than one of the characteristic listed above and therefore may have individual element that are subject to different accounting model from time to time when executing restructuring or exit plan the company also incurs cost other than termination benefit such lease termination cost that are not associated with or will not be incurred to generate revenue these include cost that represent amount under contractual obligation that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in penalty to cancel contractual obligation such cost are recognized when incurred which generally occurs at the contract termination or over the period from when plan to abandon leased facility is approved through the cease use date but charge may continue over the remainder of the original contractual period fisher scientific inc note to consolidated financial statement continued income taxesthe company recognizes deferred income tax based on the expected future tax consequence of difference between the financial statement basis and the tax basis of asset and liability calculated using enacted tax rate in effect for the year in which the difference are expected to be reflected in the tax return the financial statement reflect expected future tax consequence of uncertain tax position that the company ha taken or expects to take on tax return presuming the taxing authority full knowledge of the position and all relevant fact but without discounting for the time value of money note earnings per sharebasic earnings per share ha been computed by dividing net income by the weighted average number of share outstanding during the year except where the result would be antidilutive to income from continuing operation diluted earnings per share ha been computed using the treasury stock method for outstanding stock option and restricted unit note cash and cash equivalentscash equivalent consists principally of money market fund commercial paper and other marketable security purchased with an original maturity of three month or le these investment are carried at cost which approximates market value inventoriesinventories are valued at the lower of cost or net realizable value cost being determined principally by the first in first out fifo method with certain of the company business utilizing the last in first out lifo method the company periodically review quantity of inventory on hand and compare these amount to the expected use of each product or product line in addition the company ha certain inventory that is subject to fluctuating market pricing the company ass the carrying value of this inventory based on lower of cost or net realizable value analysis the company record charge to cost of sale for the amount required to reduce the carrying value of inventory to net realizable value cost associated with the procurement of inventory such inbound freight charge purchasing and receiving cost and internal transfer cost are included in cost of revenue in the accompanying statement of income the component of inventory are follows december december in million material work in finished inventory the value of inventory maintained using the lifo method wa million and million at december and respectively which wa below estimated replacement cost by million and million respectively reduction to cost of revenue result of the liquidation of lifo inventory were nominal during the three year ended december property plant and equipmentproperty plant and equipment are recorded at cost the cost of addition and improvement are capitalized while maintenance and repair are charged to expense incurred the company provides for depreciation and amortization using the straight line method over the estimated useful life of the property follows building and improvement to year machinery and equipment including software to year and leasehold improvement the shorter of the term of the lease or the life of the asset when asset are retired or otherwise disposed of the asset and related accumulated depreciation are eliminated from the account and the resulting gain or loss is reflected in the accompanying statement of income property plant and equipment consists of the following fisher scientific inc note to consolidated financial statement continued december december in million building and machinery equipment and leasehold property plant and equipment at le accumulated depreciation and property plant and equipment net depreciation and amortization expense of property plant and equipment wa million million and million in and respectively acquisition related intangible assetsacquisition related intangible asset include the cost of acquired customer relationship product technology tradenames and other specifically identifiable intangible asset and are being amortized using the straight line method over their estimated useful life which range from to year in addition the company ha tradenames and in process research and development that have indefinite life and which are not amortized the company review intangible asset for impairment when indication of potential impairment exists such significant reduction in cash flow associated with the asset intangible asset with indefinite life are reviewed for impairment annually or whenever event or change in circumstance indicate they may be impaired acquisition related intangible asset are follows balance at december at december in million grossaccumulated amortizationnetgross accumulated amortizationnetdefinite lived customer relationship product indefinite lived in process research and acquisition related intangible asset the estimated future amortization expense of acquisition related intangible asset with definite life is follows in million and estimated future amortization expense of definite lived intangible asset fisher scientific inc note to consolidated financial statement continued amortization of acquisition related intangible asset wa billion billion and billion in and respectively other assetsother asset in the accompanying balance sheet include operating lease right of use asset deferred tax asset pension asset cash surrender value of life insurance insurance recovery receivables related to product liability matter investment and other asset prior to january investment for which there are not readily determinable market value were accounted for under the cost method of accounting the company periodically evaluated the carrying value of it investment accounted for under the cost method of accounting which provided that they are recorded at the lower of cost or estimated net realizable value effective january equity investment that do not have readily determinable fair value are measured at cost minus impairment if any plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer the company performs qualitative assessment to identify impairment of these investment at december and the company had such investment with carrying amount of million and million respectively which are included in other asset goodwillthe company ass goodwill for impairment at the reporting unit level annually and whenever event occur or circumstance change that would more likely than not reduce the fair value of reporting unit below it carrying amount such event or circumstance generally include the occurrence of operating loss or significant decline in earnings associated with one or more of the company reporting unit the company is permitted to first ass qualitative factor to determine whether the goodwill impairment test is necessary if the qualitative assessment result in determination that the fair value of reporting unit is more likely than not le than it carrying amount the company performs quantitative goodwill impairment test the company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test the company estimate the fair value of it reporting unit by using forecast of discounted future cash flow and peer market multiple the company would record an impairment charge based on the excess of reporting unit carrying amount over it fair value limited to the amount of goodwill the company determined that no impairment existed in or the change in the carrying amount of goodwill by segment are follows in million life sciencessolutionsanalyticalinstrumentsspecialtydiagnosticslaboratoryproducts andservicestotalbalance at december finalization of purchase price allocation for acquisition currency translation balance at december acquisition finalization of purchase price allocation for acquisition sale of business currency translation balance at december loss contingenciesaccruals are recorded for various contingency including legal proceeding environmental worker compensation product general and auto liability self insurance and other claim that arise in the normal course of business the accrual are based on management judgment historical claim experience the probability of loss and where applicable the consideration of opinion of internal and or external legal counsel and actuarial estimate additionally the company record fisher scientific inc note to consolidated financial statement continued receivables from third party insurer up to the amount of the loss when recovery ha been determined to be probable liability acquired in acquisition have been recorded at fair value and such were discounted to present value at the date of acquisition currency translationall asset and liability of the company non subsidiary are translated at period end exchange rate resulting translation adjustment are reflected in the accumulated other comprehensive item component of shareholder equity revenue and expense are translated at average exchange rate for the period currency transaction gain loss are included in the accompanying statement of income and in aggregate were million million and million in and respectively derivative contractsthe company is exposed to certain risk relating to it ongoing business operation including change to interest rate and currency exchange rate the company us derivative instrument primarily to manage currency exchange and interest rate risk the company recognizes derivative instrument either asset or liability and measure those instrument at fair value if derivative is hedge depending on the nature of the hedge change in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive item until the hedged item is recognized in earnings derivative that are not designated hedge are recorded at fair value through earnings the company us short term forward and option currency exchange contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate predominantly intercompany loan and cash balance that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in swiss franc euro canadian dollar swedish kronor british pound sterling japanese yen and czech koruna the company doe not hold or engage in transaction involving derivative instrument for purpose other than risk management cash flow hedge for derivative instrument that are designated and qualify cash flow hedge the gain or loss on the derivative is reported component of other comprehensive item and reclassified into earnings in the same period or period during which the hedged transaction affect earnings and is presented in the same income statement line item the earnings effect of the hedged item fair value hedge for derivative instrument that are designated and qualify fair value hedge the gain or loss on the derivative well the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in earnings net investment hedge the company also us foreign currency denominated debt and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate the majority of the company euro denominated senior note and cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity use of estimatesthe preparation of financial statement in conformity with generally accepted accounting principle requires management to make estimate and assumption that affect the reported amount of asset and liability disclosure of contingent asset and liability at the date of the financial statement and the reported amount of revenue and expense during the reporting period actual result could differ from those estimate recent accounting pronouncementsin january the fasb issued new guidance to clarify the interaction of the accounting for certain equity security equity method investment and certain forward contract and purchased option among other thing the new guidance clarifies that an entity should consider observable transaction that require it to either apply or discontinue the equity method of accounting for the purpose of applying measurement principle for certain equity security immediately before applying or discontinuing the equity method the company expects to adopt this guidance in using prospective method the adoption of this guidance is not expected to have material impact on the company consolidated financial statement in december the fasb issued new guidance to simplify the accounting for income tax among other thing the new guidance requires the effect of enacted change in tax law or rate to be reflected in the annual effective tax rate fisher scientific inc note to consolidated financial statement continued computation in the interim period that includes the enactment date the company expects to adopt this guidance when it is effective in using prospective method the adoption of this guidance is not expected to have material impact on the company consolidated financial statement however the impact in future period will be dependent on the extent of future event or condition that would be affected such enacted change in tax law or rate in august the fasb issued new guidance to modify the disclosure requirement for employer that sponsor defined benefit pension or other postretirement plan the company will adopt the guidance in using retrospective method the adoption of this guidance is not expected to have material impact on the company disclosure in august the fasb issued new guidance to modify the disclosure requirement on fair value measurement the company will adopt the guidance in with some item requiring prospective method and others requiring retrospective method the adoption of this guidance is not expected to have material impact on the company disclosure in february the fasb issued new guidance to allow reclassification from accumulated other comprehensive item aoci to retained earnings for certain tax effect on item within aoci resulting from the tax cut and job act of the tax act the company adopted this guidance in january and recorded the reclassification in the period of adoption the balance sheet impact of adopting this guidance is included in the table below this guidance only relates to the effect of the tax act for all other tax law change that have occurred or may occur in the future the company reclassifies the tax effect to the consolidated statement of income on an item by item basis when the pre tax item in aoci is reclassified to income in december the sec staff issued guidance to address the application of accounting guidance in situation when registrant doe not have the necessary information available prepared or analyzed including computation in reasonable detail to complete the accounting for certain income tax effect of the tax act enacted on december the company reported provisional amount in it financial statement for certain income tax effect of the tax act for which reasonable estimate could be determined adjustment to provisional amount identified during the measurement period which ended december are included adjustment to provision for income tax in note in august the fasb issued new guidance to simplify the application of hedge accounting guidance among other thing the new guidance will permit more hedging strategy to qualify for hedge accounting allow for additional time to perform an initial assessment of hedge effectiveness and permit qualitative effectiveness test for certain hedge after initial qualification the company adopted this guidance in january the balance sheet impact of adopting this guidance is included in the table below in october the fasb issued new guidance eliminating the deferral of the tax effect of intra entity asset transfer the impact of this guidance in future period will be dependent on the extent of future asset transfer which usually occur in connection with planning around acquisition and other business structuring activity the balance sheet impact of adopting this guidance of january is included in the table below in june the fasb issued new guidance to require financial asset measured at amortized cost basis such account receivable to be presented at the net amount expected to be collected based on relevant information about past event including historical experience current condition and reasonable and supportable forecast that affect the collectability of the reported amount during and the fasb issued additional guidance and clarification the company will adopt the guidance in using modified retrospective method the adoption of this guidance is not expected to have material impact on the company consolidated financial statement in february the fasb issued new guidance which requires lessee to record most lease on their balance sheet lease liability initially measured at the present value of the future lease payment with corresponding right of use asset the new guidance also set forth new disclosure requirement related to lease during the fasb issued additional guidance and clarification the company adopted this guidance in january the company elected to adopt the guidance using modified retrospective method by applying the transition approach of the beginning of the period of adoption comparative period have not been restated permitted upon transition the company did not reassess whether any expired or existing contract were or contained embedded lease the lease classification for any expired or existing lease initial direct cost for any lease or whether land easement met the definition of lease if they were not accounted for lease under the prior guidance adoption of the new guidance impacted the company consolidated balance sheet follows fisher scientific inc note to consolidated financial statement continued in million december reportedimpact of adopting new lease guidancejanuary adoptedother asset other accrued other long term retained in january the fasb issued new guidance which affect the accounting for equity investment financial liability under the fair value option and the presentation and disclosure requirement for financial instrument this guidance requires equity investment to be measured at fair value with subsequent change recognized in net income except for those accounted for under the equity method or requiring consolidation the guidance also change the accounting for investment without readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value the balance sheet impact of adopting this guidance of january is included in the table below in may the fasb issued new revenue recognition guidance which provides single comprehensive model for entity to use in accounting for revenue arising from contract with customer and supersedes most previous revenue recognition guidance the new standard also requires significantly expanded disclosure regarding the qualitative and quantitative information of an entity nature amount timing and uncertainty of revenue and cash flow arising from contract with customer during and the fasb issued additional guidance and clarification including the elimination of certain sec staff guidance the guidance is effective for the company in the company elected to adopt this guidance through application of the modified retrospective method by applying it to contract that were not completed of december in addition to new contract in adoption of new guidance that became effective on january impacted the company consolidated balance sheet follows in million december reportedimpact of adopting new revenue guidanceimpact of adopting new equity investment guidanceimpact of adopting new intra entity tax guidanceimpact of adopting new hedge accounting guidanceimpact of adopting new tax effect on item in aoci guidancejanuary adoptedaccounts receivable le allowance other current other deferred contract liability other accrued deferred income other long term long term retained accumulated other comprehensive item had the company continued to use the revenue recognition guidance in effect prior to no material change would have resulted to the consolidated statement of income comprehensive income or cash flow for the year ended december from amount reported therein however inventory would have been million higher and other current asset would have been million lower of december primarily result of difference in the accounting for pharmaceutical development and manufacturing service under the new revenue guidance under the prior guidance cost of these service were recorded in inventory and revenue were recognized generally when the product were delivered to customer under the new guidance cost are expensed and revenue are recognized the manufacturing service is performed and the company right to consideration are recorded contract asset fisher scientific inc note to consolidated financial statement continued note acquisition and dispositionsthe company acquisition have historically been made at price above the determined fair value of the acquired identifiable net asset resulting in goodwill due to expectation of the synergy that will be realized by combining the business these synergy include the elimination of redundant facility function and staffing use of the company existing commercial infrastructure to expand sale of the acquired business product and use of the commercial infrastructure of the acquired business to cost effectively expand sale of company product acquisition have been accounted for using the acquisition method of accounting and the acquired company result have been included in the accompanying financial statement from their respective date of acquisition acquisition transaction cost are recorded in selling general and administrative expense incurred april the company acquired within the laboratory product and service segment brammer bio for approximately billion in cash brammer bio is leading viral vector contract development and manufacturing organization for gene and cell therapy the acquisition expands the segment contract manufacturing capability brammer bio reported revenue of approximately million in the purchase price exceeded the fair value of the identifiable net asset and accordingly million wa allocated to goodwill million of which is tax deductible in addition in the company acquired within the analytical instrument segment slovakia based provider of mass spectrometry software used for identification of compound and within the laboratory product and service segment an active pharmaceutical ingredient api manufacturing facility in cork ireland for an aggregate purchase price of million the component of the purchase price and net asset acquired for acquisition are follows in million brammer bioothertotalpurchase pricecash paid cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product other contract liability deferred tax liability other liability assumed the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology and year for tradenames the weighted average amortization period for all definite lived intangible asset acquired in is year october the company acquired within the life science solution segment becton dickinson and company advanced bioprocessing business for million in cash this north america based business add complementary cell culture product that expand the segment bioproduction offering to help customer increase yield during production of biologic drug the advanced bioprocessing business reported revenue of million in the purchase price exceeded the fair value of the identifiable net asset and accordingly million wa allocated to goodwill all of which is tax deductible fisher scientific inc note to consolidated financial statement continued in the company acquired within the life science solution segment north america based provider of rapid dna platform for use in forensics and law enforcement application for an aggregate purchase price of million the component of the purchase price and net asset acquired for acquisition are follows in million advanced bioprocessing businessothertotalpurchase pricecash paid fair value of contingent consideration cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product indefinite lived intangible asset in process research and development other asset deferred tax liability other liability assumed the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology and year for tradenames the weighted average amortization period for all definite lived intangible asset acquired in is year august the company acquired within the laboratory product and service segment patheon leading global provider of high quality drug development and delivery solution to the pharmaceutical and biopharma sector for per share in cash or billion including the assumption of net debt the company financed the purchase price including the repayment of indebtedness of patheon with issuance of debt and equity patheon provides comprehensive integrated and highly customizable solution well the expertise to help biopharmaceutical company of all size satisfy complex development and manufacturing need the acquisition provided entry into the pharmaceutical contract development and manufacturing organization market and added complementary service to the company existing pharmaceutical service portfolio patheon reported revenue of billion for the year ended october the purchase price exceeded the fair market value of the identifiable net asset and accordingly billion wa allocated to goodwill million of which is tax deductible in addition in the company acquired within the analytical instrument segment north america based provider of cloud based platform supporting scientific data management within the life science solution segment north america based developer of scalable control automation system and software for bioproduction within the specialty diagnostics segment north america based molecular diagnostics company offering qpcr test to the transplant community and within the analytical instrument segment provider of desktop scanning electron microscopy solution and manufacturer of volatile organic compound monitoring instrument and integrated system for an aggregate purchase price of million fisher scientific inc note to consolidated financial statement continued the component of the purchase price and net asset acquired for acquisition are follows in million patheonothertotalpurchase pricecash paid debt fair value of contingent consideration fair value of equity award fair value of previously held interest cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product technology indefinite lived intangible asset in process research and development other deferred tax liability other liability assumed the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology and year for tradenames the weighted average amortization period for all definite lived intangible asset acquired in is year unaudited pro forma informationthe following unaudited pro forma information provides the effect of the company acquisition of patheon if the acquisition had occurred on january in million net income to reflect the acquisition of patheon if it had occurred on january the unaudited pro forma result include adjustment to reflect among other thing the incremental intangible asset amortization to be incurred based on the preliminary value of each identifiable intangible asset and the interest expense from debt financing obtained to partially fund the cash consideration transferred pro forma adjustment were tax effected at the company historical statutory rate in effect for the respective period the unaudited pro forma amount are not necessarily indicative of the combined result of operation that would have been realized had the acquisition and related financing occurred on the aforementioned date are they meant to be indicative of any anticipated combined result of operation that the company will experience after the transaction in addition the amount do not include any adjustment for action that may be taken following the completion of the transaction such expected cost saving operating synergy or revenue enhancement that may be realized subsequent to the transaction pro forma net income for the year ended december excludes certain item associated with the patheon acquisition that were included in the determination of net income for that period these item have been included in the determination of pro forma net income for the year ended december not presented and are follows million fisher scientific inc note to consolidated financial statement continued of direct transaction cost million of accounting policy conformity adjustment million of initial restructuring cost million reduction of revenue for revaluing the deferred revenue obligation to fair value and million of expense related to the fair value adjustment to acquisition date inventory the company result would not have been materially different from it pro forma result had the company other or acquisition occurred at the beginning of or respectively dispositionon june the company sold it anatomical pathology business to phc holding corporation for billion net of cash divested the business wa part of the specialty diagnostics segment the sale of this business resulted in pre tax gain of approximately million included in restructuring and other income cost net revenue in through the date of sale and the full year of the business sold were approximately million and million respectively net of retained sale through the company healthcare market and research and safety market channel business the asset and liability of the anatomical pathology business were follows on december in million december asset long term current long term note revenue disaggregated revenuerevenue by type is follows in million consolidated revenue revenue by geographic region is follows in million north america asia other consolidated revenue revenue are attributed to region based on customer location each reportable segment earns revenue from consumables instrument and service in north america europe asia pacific and other region see note for revenue by reportable segment and other geographic data remaining performance obligationsthe aggregate amount of the transaction price allocated to the remaining performance obligation for all open customer contract of december wa billion the company will recognize revenue for these performance obligation they are satisfied approximately of which is expected to occur within the next twelve month fisher scientific inc note to consolidated financial statement continued note business segment and geographical information the company financial performance is reported in four segment description of each segment follows life science solution provides an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of disease these product and service are used by customer in pharmaceutical biotechnology agricultural clinical academic and government market analytical instrument provides broad offering of instrument consumables software and service that are used for range of application in the laboratory on the production line and in the field these product and service are used by customer in pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory specialty diagnostics provides wide range of diagnostic test kit reagent culture medium instrument and associated product used to increase the speed and accuracy of diagnosis these product are used by customer in healthcare clinical pharmaceutical industrial and food safety laboratory laboratory product and service provides virtually everything needed for the laboratory including combination of self manufactured and sourced product for customer in research academic government industrial and healthcare setting the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical trial logistics and commercial drug manufacturing the company management evaluates segment operating performance based on operating income before certain charge credit to cost of revenue and selling general and administrative expense principally associated with acquisition accounting restructuring and other cost income including cost arising from facility consolidation such severance and abandoned lease expense and gain and loss from the sale of real estate and product line well from significant litigation related matter and amortization of acquisition related intangible asset the company us this measure because it help management understand and evaluate the segment core operating result and facilitates comparison of performance for determining compensation fisher scientific inc note to consolidated financial statement continued business segment information in million science solution analytical specialty laboratory product and elimination consolidated segment income life science analytical specialty laboratory product and subtotal reportable segment cost of revenue charge net selling general and administrative charge net restructuring and other income cost amortization of acquisition related intangible asset consolidated operating interest income interest expense other expense income net income from continuing operation before income tax depreciationlife science solution analytical specialty laboratory product and consolidated depreciation represents operating income before certain charge to cost of revenue and selling general and administrative expense restructuring and other cost income net and amortization of acquisition related intangible the company doe not allocate interest or other expense income net to it segment fisher scientific inc note to consolidated financial statement continued in million assetslife science solution analytical specialty laboratory product and corporate other consolidated total asset capital expenditureslife science solution analytical specialty laboratory product and corporate consolidated capital expenditure corporate asset consist primarily of cash and cash equivalent and property and equipment at the company corporate office geographical information in million united state consolidated revenue long lived asset united state consolidated long lived asset revenue are attributed to country based on customer location includes property plant and equipment net and beginning in operating lease right of use asset note other expense income net in all period other expense net includes currency transaction gain and loss on monetary asset and liability and net periodic pension benefit cost income excluding the service cost component which is included in operating expense on the accompanying statement of income in other expense net includes million of loss on the early extinguishment of debt see note offset in part by million of net gain on investment the investment gain include million gain on the sale of joint venture for net proceeds of million in other expense net also includes million of net loss on investment in other expense net includes million of charge related to amortization of fee paid to obtain bridge financing commitment related to the patheon acquisition note and million of loss on the early extinguishment of debt offset in part by million of net gain on investment fisher scientific inc note to consolidated financial statement continued note stock based compensation expense the company ha stock based compensation plan for it key employee director and others these plan permit the grant of variety of stock and stock based award including restricted stock unit stock option or performance based share determined by the compensation committee of the company board of director or for certain non officer grant by the company employee equity committee which consists of it chief executive officer the company generally issue new share of it common stock to satisfy option exercise and restricted unit vestings grant of stock option and restricted unit generally provide that in the event of both change in control of the company and qualifying termination of an option or unit holder employment all option and service based restricted unit award held by the recipient become immediately vested unless an employment or other agreement with the employee provides for different treatment compensation cost is based on the grant date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility if earlier stock based compensation expense is primarily included in selling general and administrative expense in million based compensation expense stock optionsthe company practice is to grant stock option at fair market value option vest over year with term of year assuming continued employment with certain exception vesting of the option award is contingent upon meeting certain service condition the fair value of most option grant is estimated using the black scholes option pricing model for option grant that require the achievement of both service and market condition lattice model is used to estimate fair value the fair value is then amortized on straight line basis over the requisite service period of the award which is generally the vesting period use of valuation model requires management to make certain assumption with respect to selected model input expected volatility wa calculated based on the historical volatility of the company stock historical data on exercise pattern is the basis for estimating the expected life of an option the risk free interest rate is based on treasury zero coupon issue with remaining term which approximates the expected life assumed at the date of grant the expected annual dividend rate wa calculated by dividing the company annual dividend based on the most recent quarterly dividend rate by the closing stock price on the grant date the compensation expense recognized for all stock based award is net of estimated forfeiture forfeiture are estimated based on an analysis of actual option forfeiture the weighted average assumption used in the black scholes option pricing model are follows stock price risk free interest expected life of option year annual the weighted average per share grant date fair value of option granted during and were and respectively the total intrinsic value of option exercised during the same period wa million million and million respectively the intrinsic value is the difference between the market value of the share on the exercise date and the exercise price of the option fisher scientific inc note to consolidated financial statement continued summary of the company option activity for the year ended december is presented below share in million weighted average exercise priceweighted average remaining contractual term in year aggregate intrinsic value in million outstanding at december exercised canceled expired outstanding at december and unvested expected to vest at december exercisable at december of december there wa million of total unrecognized compensation cost related to unvested stock option granted the cost is expected to be recognized through with weighted average amortization period of year restricted share unit awardsawards of restricted unit convert into an equivalent number of share of common stock the award generally vest over year assuming continued employment with some exception vesting of the award is contingent upon meeting certain service condition and may also be contingent upon meeting certain performance and or market condition the fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award which is generally the vesting period recipient of restricted unit have no voting right but are entitled to accrue dividend equivalent the fair value of service and performance based restricted unit award is determined based on the number of unit granted and the market value of the company share on the grant date for award with market based vesting condition the company us lattice model to estimate the grant date fair value of the award summary of the company restricted unit activity for the year ended december is presented below unit in million weightedaveragegrant datefair valueunvested at december vested forfeited unvested at december the total fair value of share vested during and wa million million and million respectively of december there wa million of total unrecognized compensation cost related to unvested restricted stock unit award the cost is expected to be recognized through with weighted average amortization period of year employee stock purchase plansqualifying employee are eligible to participate in an employee stock purchase plan sponsored by the company share may be purchased under the program at of the fair market value at the end of the purchase period and the share purchased are not subject to holding period share are purchased through payroll deduction of up to of each participating fisher scientific inc note to consolidated financial statement continued employee qualifying gross wage the company issued million million and million share respectively of it common stock in and under the employee stock purchase plan note pension and other postretirement benefit plan saving plan and other defined contribution plansthe company saving and other defined contribution plan cover the majority of the company eligible and certain non employee contribution to the plan are made by both the employee and the company company contribution are based on the level of employee contribution company contribution to these plan are based on formula determined by the company in and the company charged to expense million million and million respectively related to it defined contribution plan defined benefit pension plansemployees of number of the company non and certain subsidiary participate in defined benefit pension plan covering substantially all full time employee at those subsidiary some of the plan are unfunded permitted under the plan and applicable law the company also maintains postretirement healthcare program at several acquired business where certain employee are eligible to participate the cost of the postretirement healthcare program are generally funded on self insured and insured premium basis the company recognizes the funded status of defined benefit pension and other postretirement benefit plan an asset or liability this amount is defined the difference between the fair value of plan asset and the benefit obligation the company is required to recognize component of other comprehensive item net of tax the actuarial gain loss and prior service cost credit that arise but were not previously required to be recognized component of net periodic benefit cost other comprehensive item is adjusted these amount are later recognized in income component of net periodic benefit cost when company with pension plan is acquired any excess of projected benefit obligation over the plan asset is recognized liability and any excess of plan asset over the projected benefit obligation is recognized an asset the recognition of new liability or new asset result in the elimination of previously existing unrecognized net gain or loss and unrecognized prior service cost or credit the company fund annually at minimum the statutorily required minimum amount actuarially determined during and the company made cash contribution of approximately million million and million respectively contribution to the plan included in the following table are estimated at between and million for fisher scientific inc note to consolidated financial statement continued the following table provides reconciliation of benefit obligation and plan asset of the company domestic and non pension plan and postretirement benefit plan domestic pension benefitsnon pension benefitspostretirementbenefits in million in projected benefit obligationsbenefit obligation at beginning of year business combination divestiture service cost interest settlement plan participant contribution actuarial gain benefit paid currency translation and other benefit obligation at end of year change in fair value of plan assetsfair value of plan asset at beginning of year business combination divestiture actual return on plan employer settlement plan participant contribution benefit paid currency translation and other fair value of plan asset at end of year funded status accumulated benefit obligation amount recognized in balance sheetnoncurrent asset current liability noncurrent liability net amount recognized amount recognized in accumulated other comprehensive itemsnet actuarial loss prior service credit net amount recognized fisher scientific inc note to consolidated financial statement continued the actuarial assumption used to compute the funded status for the plan are based upon information available of december and and are follows domestic pensionbenefitsnon pensionbenefitspostretirementbenefits average assumption used to determine projected benefit obligationsdiscount average rate of increase in employee compensationn initial healthcare cost trend ultimate healthcare cost trend the actuarial assumption used to compute the net periodic pension benefit cost income are based upon information available of the beginning of the year presented in the following table domestic pension benefitsnon pension benefit average assumption used to determine net benefit cost income discount average rate of increase in employee compensationn expected long term rate of return on the ultimate healthcare cost trend rate for the postretirement benefit plan are expected to be reached between and the discount rate reflects the rate the company would have to pay to purchase high quality investment that would provide cash sufficient to settle it current pension obligation the discount rate is determined based on range of factor including the rate of return on high quality fixed income corporate bond and the related expected duration of the obligation or in certain instance the company ha used hypothetical portfolio of high quality instrument with maturity that mirror the benefit obligation in order to accurately estimate the discount rate relevant to particular plan the company utilizes full yield curve approach in the estimation of these component by applying the specific spot rate along the yield curve used in the determination of the benefit obligation to the relevant projected cash flow the expected long term rate of return on plan asset reflects the average rate of earnings expected on the fund invested or to be invested to provide for the benefit included in the projected benefit obligation in determining the expected long term rate of return on plan asset the company considers the relative weighting of plan asset the historical performance of total plan asset and individual asset class and economic and other indicator of future performance in addition the company may consult with and consider the opinion of financial and other professional in developing appropriate return benchmark asset management objective include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirement the expected rate of compensation increase reflects the long term average rate of salary increase and is based on historic salary increase experience and management expectation of future salary increase the amount in accumulated other comprehensive item expected to be recognized component of net periodic benefit cost in are not material fisher scientific inc note to consolidated financial statement continued the projected benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with projected benefit obligation in excess of plan asset are follows pension plan in million plan with projected benefit obligation in excess of plan assetsprojected benefit obligation fair value of plan the accumulated benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with accumulated benefit obligation in excess of plan asset are follows pension plan in million plan with accumulated benefit obligation in excess of plan assetsaccumulated benefit obligation fair value of plan the measurement date used to determine benefit information is december for all plan asset and benefit obligation the net periodic pension benefit cost income includes the following component domestic pension benefitsnon pension benefit in million of net benefit cost income service cost benefit earned interest cost on benefit expected return on plan asset amortization of actuarial net amortization of prior service benefit settlement curtailment loss net periodic benefit cost income the net periodic postretirement benefit cost wa not material in and expected benefit payment are estimated using the same assumption used in determining the company benefit obligation at december benefit payment will depend on future employment and compensation level average year employed and average life span among other factor and change in any of these factor could significantly affect these estimated future benefit payment estimated future benefit payment during the next five year and in the aggregate for the five fiscal year thereafter are follows in million domesticpensionbenefitsnon pensionbenefitspost retirementbenefitsexpected benefit change in the assumed healthcare cost trend rate by one percentage point effective january would not have caused material change in the accumulated postretirement benefit obligation of december and the aggregate of service and interest cost fisher scientific inc note to consolidated financial statement continued domestic pension plan assetsthe company overall objective is to manage the asset in liability framework where investment are selected that are expected to have similar change in fair value the related liability will have upon change in interest rate the company invests in portfolio of both return seeking and liability hedging asset primarily through the use of institutional collective fund to achieve long term growth and to insulate the funded position from interest rate volatility the strategic asset allocation us combination of risk controlled and index strategy in fixed income and global equity the target allocation for the investment are approximately to fund investing in equity approximately to fund investing in international equity and approximately to fund investing in fixed income security the portfolio maintains enough liquidity at all time to meet the near term benefit payment non pension plan assetsthe company maintains specific plan asset for many of the individual pension plan outside the the investment strategy of each plan ha been uniquely established based on the country specific standard and characteristic of the plan several of the plan have contract with insurance company whereby the market risk of the benefit obligation are borne by the insurance company when asset are held directly in investment generally the objective is to invest in portfolio of diversified asset with variety of fund manager the investment may include equity fund fixed income fund hedge fund multi asset fund alternative investment and derivative fund with the target asset allocation ranging from approximately for equity fund for fixed income fund for hedge fund for multi asset fund to for alternative investment and for fund holding derivative the derivative held by the fund are primarily interest rate swap intended to match the movement in the plan liability well equity future in synthetic equity fund which provide targeted exposure to equity market without the fund holding individual equity position each plan maintains enough liquidity at all time to meet the near term benefit payment the fair value of the company plan asset at december and by asset category are follows december quoted pricesin activemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income hedge multi asset derivative alternative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy fisher scientific inc note to consolidated financial statement continued december quoted pricesin activemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income hedge multi asset derivative alternative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy the table above present the fair value of the company plan asset in accordance with the fair value hierarchy note certain investment that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy the fair value amount of these investment presented in the above table are intended to permit reconciliation of the fair value hierarchy to the amount presented for the total pension plan asset these investment were also redeemable at the balance sheet date or within limited time restriction note income taxesthe component of income from continuing operation before provision for income tax are follows in million non income from continuing operation fisher scientific inc note to consolidated financial statement continued the component of the provision for income tax of continuing operation are follows in million income tax provisionfederal non deferred income tax provision benefit federal non state provision for income tax the provision for income tax in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income from continuing operation before provision for income tax due to the following in million federal income tax provision for income tax at statutory rate increase decrease resulting from foreign rate differential foreign exchange loss on inter company debt refinancing income tax credit withholding global intangible low taxed foreign derived intangible income impact of change in tax law and apportionment on deferred transition tax and other impact of tax provision for reversal of tax reserve excess tax benefit from stock option and restricted stock unit basis difference on disposal of valuation allowance intra entity transfer other net provision for income tax the company ha operation and taxable presence in approximately country outside the the company effective income tax rate differs from the federal statutory rate each year due to certain operation that are subject to tax incentive state and local tax and foreign tax that are different than the federal statutory rate tax reform impactson december the tax cut and job act of wa enacted the tax act includes significant change to existing tax law that affect the company including reduction of the corporate income tax rate from to beginning in and creation of territorial tax system with one time transition tax on deemed repatriated earnings and profit of foreign subsidiary transition tax detailed below the company recognized net charge of million for certain aspect of the tax act in it financial statement for which the accounting wa provisional but reasonable fisher scientific inc note to consolidated financial statement continued estimate could be determined during the company completed it accounting for the income tax effect of the tax act and recognized net adjustment detailed below to the provisional amount totaling net charge of million component of income tax expense the transition tax is based on the company total post earnings and profit the tax on which wa previously deferred from income tax under law the company recorded provisional amount for the transition tax liability for each of the foreign subsidiary resulting in total transition liability of billion at december after further analysis of new treasury guidance available tax accounting method and election legislative update regulation earnings and profit computation and foreign tax the company finalized the calculation of the transition tax liability during the increase in the liability for the transition tax in consisted of an incremental provision of million offset in part by million reduction of related unrecognized tax benefit established in in result of the tax act the company remeasured certain deferred tax asset and liability based on the rate at which they were expected to reverse in the future which wa generally by recording provisional tax benefit of billion during no material change to this provisional amount were made the tax act included provision for global intangible low taxed income the company ha adopted policy to account for this provision period cost during the company recorded net tax provision of million to adjust the impact of tax reform based on final regulation issued by the treasury in the income tax provision consists of an incremental charge of million offset by million reduction of related unrecognized tax benefit other tax impactsin the company recorded million income tax benefit including both federal and state tax related to foreign exchange loss for tax purpose on certain intercompany financing arrangement well tax provision of million related to the gain on the sale of the anatomical pathology business also in the company recorded million benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable in the provision for income tax also included million charge to establish valuation allowance against net operating loss that will not be utilized result of the sale of the anatomical pathology business note the foreign tax credit discussed below are the result of foreign earnings and profit remitted or deemed remitted to the during the reporting year and the treatment of tax paid in the foreign jurisdiction in the year those profit were originally earned in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense in the company continued to implement tax planning initiative related to non subsidiary these non subsidiary incurred foreign tax obligation and made cash and deemed distribution to the company operation which resulted in no net tax cost result of these distribution the company benefited from foreign tax credit of million offset in part by additional income tax of million on the related foreign income which reduced the benefit from the foreign rate differential in the company also implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense in the company refinanced certain long term inter company debt which resulted in an income tax benefit of million related to foreign exchange loss recognized for income tax purpose the company generally receives tax deduction upon the exercise of non qualified stock option by employee or the vesting of restricted stock unit held by employee for the difference between the exercise price and the market price of the underlying common stock on the date of exercise the company us the incremental tax benefit approach for utilization of tax attribute these excess tax benefit reduce the tax provision in and the company tax provision wa reduced by million million and million respectively of such benefit fisher scientific inc note to consolidated financial statement continued net deferred tax asset liability in the accompanying balance sheet consists of the following in million tax asset liability depreciation and amortization net operating loss and credit reserve and accrued inventory basis other capitalized unrealized loss on hedging other deferred tax asset liability net before valuation allowance le valuation deferred tax asset liability net the company estimate the degree to which tax asset and loss and credit carryforwards will result in benefit based on expected profitability by tax jurisdiction and provides valuation allowance for tax asset and loss and credit carryforwards that it belief will more likely than not expire unutilized at december all of the company valuation allowance relates to deferred tax asset primarily net operating loss for which any subsequently recognized tax benefit will reduce income tax expense the change in the valuation allowance are follows year ended december in million balance reduction addition charged to income tax provision net addition due to acquisition reduction due to divestiture deduction currency translation and other ending balance at december the company had federal state and non net operating loss carryforwards of million billion and billion respectively use of the carryforwards is limited based on the future income of certain subsidiary the federal and state net operating loss carryforwards expire in the year through of the non net operating loss carryforwards billion expire in the year through and the remainder do not expire result of the tax act federal tax have been recorded on billion of undistributed foreign earnings of december provision ha not been made for certain state income tax or additional non tax that would be due when cash is repatriated to the the company undistributed foreign earnings are intended to be reinvested outside of the indefinitely the determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed the company intent is to only make distribution from non subsidiary in the future when they can be made at no net tax cost unrecognized tax benefitsas of december the company had billion of unrecognized tax benefit which if recognized would reduce the effective tax rate fisher scientific inc note to consolidated financial statement continued reconciliation of the beginning and ending amount of unrecognized tax benefit is follows in million balance addition due to acquisition reduction due to acquisition addition for tax position of current addition for tax position of prior reduction for tax position of prior year closure of tax year settlement ending balance substantially all of the total billion liability is classified long term liability the company doe not expect it unrecognized tax benefit to change significantly over the next twelve month during the company unrecognized tax benefit increased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position during the company unrecognized tax benefit increased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position during the company unrecognized tax benefit provisionally increased million result of uncertain tax position relating to the scope of the tax act one time transition tax million relating to foreign tax position million result of foreign exchange loss recognized on the refinancing of certain long term inter company debt and million due to an acquisition the company classified interest and penalty related to unrecognized tax benefit income tax expense the total amount of interest and penalty related to uncertain tax position and recognized in the balance sheet of december and wa million and million respectively the company conduct business globally and result thermo fisher or one or more of it subsidiary file income tax return in the federal jurisdiction and various state and foreign jurisdiction in the normal course of business the company is subject to examination by taxing authority throughout the world including such major jurisdiction australia canada china denmark finland france germany japan singapore sweden the united kingdom and the united state with few exception the company is no longer subject to federal state and local or non income tax examination for year before fisher scientific inc note to consolidated financial statement continued note earnings per share in million except per share amount from continuing operation loss from discontinued operation net income basic weighted average plus effect of stock option and restricted diluted weighted average basic earnings per share continuing operation discontinued operation basic earnings per share diluted earnings per share continuing operation discontinued operation diluted earnings per share antidilutive stock option excluded from diluted weighted average fisher scientific inc note to consolidated financial statement continued note debt and other financing arrangement effective interest rate at december december december dollar in million paper floating rate year senior note due euro denominated year senior note due year senior note due floating rate year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due year senior note due year senior note due year senior note due euro denominated year senior note due year senior note due year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due year senior note due euro denominated other total borrowing at par fair value hedge accounting adjustment unamortized discount net unamortized debt issuance cost total borrowing at carrying le short term obligation and current long term obligation the effective interest rate for the fixed rate debt include the stated interest on the note the accretion of any discount or amortization of any premium the amortization of any debt issuance cost and if applicable adjustment related to hedging see note for fair value information pertaining to the company long term obligation fisher scientific inc note to consolidated financial statement continued of december the annual repayment requirement for debt obligation are follows in million and of december short term obligation and current maturity of long term obligation in the accompanying balance sheet included million of commercial paper short term bank borrowing and borrowing under line of credit of certain of the company subsidiary the weighted average interest rate for short term borrowing wa at december no such borrowing were outstanding at december in addition to available borrowing under the company revolving credit agreement discussed below the company had unused line of credit of million of december these unused line of credit generally provide for short term unsecured borrowing at various interest rate credit facilitiesthe company ha revolving credit facility with bank group that provides for up to billion of unsecured multi currency revolving credit the facility expires in july the agreement call for interest at either libor based rate euribor based rate for fund drawn in euro or rate based on the prime lending rate of the agent bank at the company option the agreement contains affirmative negative and financial covenant and event of default customary for facility of this type the covenant in our revolving credit facility the facility include consolidated leverage ratio total debt to consolidated ebitda and consolidated interest coverage ratio consolidated ebitda to consolidated interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain maximum consolidated leverage ratio of the company ha also agreed that so long any lender ha any commitment under the facility or any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated interest coverage ratio of of the last day of any fiscal quarter of december no borrowing were outstanding under the facility although available capacity wa reduced by approximately million result of outstanding letter of credit commercial paper programsthe company ha commercial paper program pursuant to which it may issue and sell unsecured short term promissory note cp note under the program maturity may not exceed day from the date of issue and the cp note are issued on private placement basis under customary term in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment under the euro program maturity may not exceed day and may be denominated in euro dollar japanese yen british pound sterling swiss franc canadian dollar or other currency under both program the cp note are issued at discount from par or premium to par in the case of negative interest rate or alternatively are sold at par and bear varying interest rate on fixed or floating basis of december there were no outstanding borrowing under these program senior notesinterest on the floating rate senior note is payable quarterly interest is payable annually on the other euro denominated senior note and semi annually on all other senior note each of the note may be redeemed at redemption price of of the principal amount plus specified make whole premium and accrued interest the company is subject to certain affirmative and negative covenant under the indenture governing the senior note the most restrictive of which limit the ability of the company to pledge principal property security under borrowing arrangement in the company refinanced certain of it debt by issuing new senior note and using the proceeds to redeem some of it existing senior note in connection with these redemption the company incurred million of loss on the early extinguishment of debt included in other expense net on the accompanying statement of income upon redemption of the senior note the company terminated the related fixed to floating rate interest rate swap arrangement and paid million included in other financing activity net in the accompanying statement of cash flow the company also terminated related fisher scientific inc note to consolidated financial statement continued cross currency interest rate swap arrangement and received million included in other investing activity net in the accompanying statement of cash flow in thermo fisher scientific finance wholly owned finance subsidiary of the company issued the floating rate senior note due included in the table above this subsidiary ha no independent function other than financing activity the floating rate senior note due are fully and unconditionally guaranteed by the company and no other subsidiary of the company have guaranteed the obligation interest rate swap arrangementsthe company ha entered into libor based interest rate swap arrangement with various bank the aggregate amount of the swap are equal to the principal amount of the note and the payment date of the swap coincide with the interest payment date of the note the swap contract provide for the company to pay variable interest rate and receive fixed rate the variable interest rate reset monthly the swap have been accounted for fair value hedge of the note see note for additional information on the interest rate swap arrangement and related cross currency interest rate swap arrangement the following table summarizes the outstanding interest rate swap arrangement on the company senior note at december aggregate notional amountpay rate of dollar in million pay ratedecember senior note due month libor the payment on million notional value of these interest rate swap are offset in part by cross currency interest rate swap which effectively reduced the pay rate of december from weighted average of to weighted average of the company entered into million notional value of cross currency interest rate swap which effectively convert portion of the semi annual payment related to the variable rate dollar denominated libor based interest rate swap to payment on variable rate euro denominated euribor based cross currency interest rate swap note leasesas lessee the company lease certain logistics office and manufacturing facility well vehicle copier and other equipment these operating lease generally have remaining lease term between month and year and some include option to extend generally for to year or have option to terminate the arrangement within year the company finance lease are not material the company ha guaranteed the residual value of three leased operating facility with lease term ending in and the company ha agreed with the lessor to comply with certain financial covenant consistent with it other debt arrangement note the aggregate maximum guarantee under these three lease arrangement is million operating lease rou asset and lease liability for these lease arrangement are recorded on the consolidated balance sheet of december but exclude any amount for residual value guarantee lessee the consolidated statement of income includes pre tax operating lease cost of million and pre tax variable lease cost of million for the year ended december lease cost arising from finance lease short term lease and sublease income are not material cash used in operating activity for payment of amount included in the measurement of operating lease liability wa million in the year ended december operating lease rou asset of million were obtained in exchange for new operating lease liability in the year ended december the weighted average remaining operating lease term wa year and the weighted average discount rate wa of december rou asset of million of december are classified in other asset in the consolidated balance sheet operating lease liability of million and million of december are classified in other accrued expense and other long term liability respectively in the consolidated balance sheet fisher scientific inc note to consolidated financial statement continued of december future payment of operating lease liability are follows in million and total lease le imputed total operating lease liability lessor operating lease sale type lease and direct financing lease are not material previously disclosed in the company annual report on form and under previous lease accounting guidance income from continuing operation includes expense from operating lease of million and million in and respectively and the following is summary of annual future minimum lease and rental commitment under noncancelable operating lease of december in million and note commitment and contingency purchase obligationsthe company ha entered into unconditional purchase obligation in the ordinary course of business that include agreement to purchase good service or fixed asset and to pay royalty that are enforceable and legally binding and that specify all significant term including fixed or minimum quantity to be purchased fixed minimum or variable price provision and the approximate timing of the transaction purchase obligation exclude agreement that are cancelable at any time without penalty the aggregate amount of the company unconditional purchase obligation totaled billion at december and the majority of these obligation are expected to be settled during letter of credit guarantee and other commitmentsoutstanding letter of credit and bank guarantee totaled million at december substantially all of these letter of credit and guarantee expire before outstanding surety bond and other guarantee totaled million at december the expiration of these bond and guarantee range through the letter of credit bank guarantee and surety bond principally secure performance obligation and allow the holder to draw fund up to the face amount of the letter of credit bank guarantee or surety bond if the applicable business unit doe not perform contractually required the company is guarantor of pension plan obligation of divested business the purchaser of the divested business ha agreed to pay for the pension benefit however the company wa required to guarantee payment of these pension benefit should the purchaser fail to do so the amount of the guarantee at december wa million fisher scientific inc note to consolidated financial statement continued in connection with the sale of business of the company the buyer have assumed certain contractual obligation of such business and have agreed to indemnify the company with respect to those assumed liability in the event third party to transferred contract doe not recognize the transfer of obligation or buyer default on it obligation under the transferred contract the company could be liable to the third party for such obligation however in such event the company would be entitled to seek indemnification from the buyer indemnificationsin conjunction with certain transaction primarily divestiture the company ha agreed to indemnify the other party with respect to certain liability related to the business that were sold or leased property that were abandoned retention of certain environmental tax employee and product liability the scope and duration of such indemnity obligation vary from transaction to transaction where probable an obligation for such indemnification is recorded liability generally maximum obligation can not be reasonably estimated other than obligation recorded liability at the time of divestiture historically the company ha not made significant payment for these indemnification in connection with the company effort to reduce the number of facility that it occupies the company ha vacated some of it leased facility or sublet them to third party when the company sublet facility to third party it remains the primary obligor under the master lease agreement with the owner of the facility result if third party vacates the sublet facility the company would be obligated to make lease or other payment under the master lease agreement the company belief that the financial risk of default by sublessors is individually and in the aggregate not material to the company financial position or result of operation in connection with the sale of product in the ordinary course of business the company often make representation affirming among other thing that it product do not infringe on the intellectual property right of others and agrees to indemnify customer against third party claim for such infringement the company ha not been required to make material payment under such provision environmental mattersthe company is currently involved in various stage of investigation and remediation related to environmental matter the company can not predict all potential cost related to environmental remediation matter and the possible impact on future operation given the uncertainty regarding the extent of the required cleanup the complexity and interpretation of applicable law and regulation the varying cost of alternative cleanup method and the extent of the company responsibility expense for environmental remediation matter related to the cost of installing operating and maintaining groundwater treatment system and other remedial activity related to historical environmental contamination at the company domestic and international facility were not material in any period presented the company record accrual for environmental remediation liability based on current interpretation of environmental law and regulation when it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated the company calculates estimate based upon several factor including input from environmental specialist and management knowledge of and experience with these environmental matter the company includes in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site at december the company total environmental liability wa approximately million while management belief the accrual for environmental remediation are adequate based on current estimate of remediation cost the company may be subject to additional remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology or change in the conduct of the company operation which could have material adverse effect on the company financial position result of operation or cash flow litigation and related contingenciesthere are various lawsuit and claim pending against the company including matter involving product liability intellectual property employment and commercial issue the company determines the probability and range of possible loss based on the current status of each of these matter liability is recorded in the financial statement if it is believed to be probable that loss ha been incurred and the amount of the loss can be reasonably estimated the company establishes liability that is an estimate of amount expected to be paid in the future for event that have already occurred the company accrues the most likely amount or at least the minimum of the range of probable loss when range of probable loss can be estimated the accrued liability are based on management judgment to the probability of loss for asserted and unasserted claim and where applicable actuarially determined estimate accrual estimate are adjusted additional information becomes known or payment are made the amount of ultimate loss may differ from these estimate due to the inherent uncertainty associated with pending litigation or claim the company can not predict the outcome nor with respect to certain pending litigation or claim where no liability ha been accrued make meaningful estimate of the reasonably possible fisher scientific inc note to consolidated financial statement continued loss or range of loss that could result from an unfavorable outcome the company ha no material accrual for pending litigation or claim for which accrual amount are not disclosed below nor are material loss deemed probable for such matter it is reasonably possible however that an unfavorable outcome that exceeds the company current accrual estimate if any for one or more of the matter described below could have material adverse effect on the company result of operation financial position and cash flow product liability worker compensation and other personal injury mattersthe range of probable loss for product liability worker compensation and other personal injury matter of the company continuing operation at december wa approximately million to million on an undiscounted basis the portion of these liability assumed in the merger with fisher wa recorded at it fair present value at the date of merger the company accrual for all such matter in total including the discounted liability wa million at december or million undiscounted the accrual includes estimated defense cost and is gross of estimated amount due from insurer of million at december or million undiscounted that are included in other asset in the accompanying balance sheet the portion of these insurance asset assumed in the merger with fisher wa also recorded at it fair value at the date of merger in addition to the above accrual of december the company had product liability accrual of million undiscounted relating to divested business the asset and liability assumed at the fisher merger date were ascribed fair value based on the present value of expected future cash flow using discount rate equivalent to the risk free rate of interest for monetary asset with comparable maturity weighted average discount rate of the discount on the liability of approximately million and the discount on the asset of approximately million net discount million are being accreted to interest expense over the expected settlement period although the company belief that the amount accrued and estimated recovery are probable and appropriate based on available information including actuarial study of loss estimate the process of estimating loss and insurance recovery involves considerable degree of judgment by management and the ultimate amount could vary materially insurance contract do not relieve the company of it primary obligation with respect to any loss incurred the collectability of amount due from it insurer is subject to the solvency and willingness of the insurer to pay well the legal sufficiency of the insurance claim management monitor the payment history well the financial condition and rating of it insurer on an ongoing basis intellectual property matterson june unisone strategic ip filed complaint against life technology subsidiary of the company in the united state district court for the southern district of california alleging patent infringement by life technology supply chain management system software which operates with product supply center installed at customer site plaintiff seek damage for alleged willful infringement attorney fee cost and injunctive relief on august unisone filed an appeal from decision by the patent trial and appeal board ptab that found the challenged patent claim invalid the united state court of appeal for the federal circuit upheld the ptab ruling finding the challenged claim in the unisone patent invalid unisone had until march to file an appeal with the united state supreme court unisone did not appeal that decision and consequently the case before the united state district court which had been stayed pending the outcome of the ptab decision resumed with unisone filing an amended complaint on september regarding similar patent claim that were not included in the ptab proceeding on november life technology filed two additional covered business method cbm challenge with the ptab regarding unisone new patent claim on december the united state district court granted life technology motion to stay the case pending the ptab decision whether to institute cbm review of the new patent claim note comprehensive income and shareholder equity comprehensive income loss comprehensive income combine net income and other comprehensive item other comprehensive item represent certain amount that are reported component of shareholder equity in the accompanying balance sheet in the fourth quarter of the company recorded an out of period adjustment to correct an error in the accounting for income tax associated with the partial hedge of it net investment in foreign operation in through the third quarter of the adjustment affected deferred income tax and other comprehensive income and in the aggregate increased comprehensive income by million for the year ended december the adjustment doe not have any impact on the fisher scientific inc note to consolidated financial statement continued company statement of income or cash flow the company determined that the adjustment wa not material to the consolidated financial statement for any previously reported annual or interim period change in each component of accumulated other comprehensive item net of tax are follows in million currencytranslationadjustmentunrealizedlosses onhedginginstrumentspension andotherpostretirementbenefitliabilityadjustmenttotalbalance at december other comprehensive item before reclassification amount reclassified from accumulated other comprehensive net other comprehensive item balance at december shareholder equityat december the company had reserved million unissued share of it common stock for possible issuance under stock based compensation plan note fair value measurement and fair value of financial instrumentsfair value measurementsthe company us the market approach technique to value it financial instrument and there were no change in valuation technique during the company financial asset and liability carried at fair value are primarily comprised of insurance contract investment in derivative contract mutual fund holding publicly traded security and other investment in unit trust held asset to satisfy outstanding deferred compensation and retirement liability and acquisition related contingent consideration the fair value accounting guidance requires that asset and liability carried at fair value be classified and disclosed in one of the following three category level quoted market price in active market for identical asset or liability that the company ha the ability to access level observable market based input or unobservable input that are corroborated by market data such quoted price interest rate and yield curve level input are unobservable data point that are not corroborated by market data fisher scientific inc note to consolidated financial statement continued the following table present information about the company financial asset and liability measured at fair value on recurring basis of december and december december quotedprices inactivemarketssignificantotherobservable inputssignificantunobservableinputs in million level level level assetscash equivalent investment in common stock mutual fund and other similar insurance derivative total asset liabilitiesderivative contract contingent total liability december quotedprices in activemarketssignificantotherobservable inputssignificant unobservable input in million level level level assetscash equivalent bank time investment in mutual fund and other similar insurance derivative total asset liabilitiesderivative contract contingent total liability the company us the black scholes model to value it warrant the company determines the fair value of it insurance contract by obtaining the cash surrender value of the contract from the issuer the fair value of derivative contract is the estimated amount that the company would receive pay upon liquidation of the contract taking into account the change in interest rate and currency exchange rate the company determines the fair value of acquisition related contingent consideration based on the probability weighted discounted cash flow associated with such future payment change to the fair value of contingent consideration are recorded in selling general and administrative expense the following table provides rollforward of the fair value determined by level input of the contingent consideration fisher scientific inc note to consolidated financial statement continued in million considerationbeginning balance acquisition including assumed balance payment change in fair value included in earnings ending balance derivative contractsthe following table provides the aggregate notional value of outstanding derivative contract december december in million amountinterest rate swap described in note cross currency interest rate swap designated net investment currency exchange while certain derivative are subject to netting arrangement with counterparties the company doe not offset derivative asset and liability within the consolidated balance sheet the following table present the fair value of derivative instrument in the consolidated balance sheet and statement of income fair value assetsfair value liability december december december december in million designated hedging instrumentsinterest rate swap cross currency interest rate swap derivative not designated hedging instrumentscurrency exchange contract total derivative the fair value of the interest rate swap is included in the consolidated balance sheet under the caption other long term liability the fair value of the cross currency interest rate swap is included in the consolidated balance sheet under the caption other asset the fair value of the currency exchange contract is included in the consolidated balance sheet under the caption other current asset or other accrued expense the following amount related to cumulative basis adjustment for fair value hedge were included in the consolidated balance sheet under the caption long term obligation carrying amount of the hedged liability cumulative amount of fair value hedging adjustment increase decrease included in carrying amount of liability december december december december in million term obligation includes increase in the carrying amount of million at december on discontinued hedging relationship fisher scientific inc note to consolidated financial statement continued gain loss recognized in million value hedging relationshipsinterest rate swapshedged long term obligation included in other expense net derivative designated hedging instrument included in other expense derivative designated cash flow hedgesinterest rate swapsincluded in unrealized loss on hedging instrument within other comprehensive item amount reclassified from accumulated other comprehensive item to other expense net financial instrument designated net investment hedgesforeign currency denominated debtincluded in currency translation adjustment within other comprehensive cross currency interest rate swapsincluded in currency translation adjustment within other comprehensive included in other expense derivative not designated hedging instrumentscurrency exchange contractsincluded in cost of product included in other expense gain and loss recognized on currency exchange contract and the interest rate swap designated fair value hedge are included in the consolidated statement of income together with the corresponding offsetting loss and gain on the underlying hedged transaction the company also us foreign currency denominated debt and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate the majority of the company euro denominated senior note and cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity see note and note for additional information on the company risk management objective and strategy cash flow hedge arrangementsin the company entered into interest rate swap arrangement to mitigate the risk of interest rate rising prior to the completion of debt offering based on the company conclusion that the debt offering were probable the swap hedged the cash flow risk for each of the interest payment on billion plus million aggregate principal amount of the planned fixed rate debt issue the hedge were terminated in in connection with the debt offering the aggregate fair value of the hedge at that time million net of tax ha been classified reduction to accumulated other comprehensive item and will be amortized to interest expense over the term of the related debt issuance the company had cash outlay of million in associated with termination of the arrangement included in other financing activity net in the accompanying statement of cash flow fisher scientific inc note to consolidated financial statement continued fair value of other financial instrumentsthe carrying value and fair value of the company note receivable and debt obligation are follows december in million valuevaluevaluevaluedebt obligation senior note commercial paper the fair value of debt obligation wa determined based on quoted market price and on borrowing rate available to the company at the respective period end which represent level measurement note supplemental cash flow information in million paid for interest income non cash investing and financing activitiesdeclared but unpaid issuance of stock upon vesting of restricted stock cash cash equivalent and restricted cash is included in the consolidated balance sheet follows december december in million and cash equivalent restricted cash included in other current restricted cash included in other cash cash equivalent and restricted cash amount included in restricted cash represent fund held collateral for bank guarantee and incoming cash in china awaiting government administrative clearance note restructuring and other cost income net restructuring and other cost income net in primarily included the gain on the sale of the company anatomical pathology business and to lesser extent transaction integration cost related to acquisition and divestiture sale of inventory revalued at the date of acquisition and continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the and europe in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce restructuring and other cost in included continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the and europe third party transaction integration cost primarily related to recent acquisition sale of inventory revalued at the date of acquisition and environmental remediation charge these charge were partially offset by gain on sale of real estate and favorable result of litigation in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce fisher scientific inc note to consolidated financial statement continued restructuring and other cost in included continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the europe and asia cost to achieve synergy related to acquisition including severance and abandoned facility cost third party acquisition transaction and integration cost primarily associated with the acquisition of fei and patheon sale of inventory revalued at the date of acquisition charge to conform the accounting policy of patheon to the company accounting policy charge for change in estimate of acquisition contingent consideration hurricane response impairment cost net charge for the settlement curtailment of retirement plan and net credit for litigation matter in severance action associated with facility consolidation and cost reduction measure affected le than of the company workforce of february the company ha identified restructuring action that will result in additional charge of approximately million primarily in and expects to identify additional action during which will be recorded when specified criterion are met such communication of benefit arrangement or when the cost have been incurred the company recorded net restructuring and other cost by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts income nettotallife science solution analytical instrument specialty diagnostics laboratory product and corporate the principal component of net restructuring and other cost by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other charge including million of charge to cost of revenue for the sale of inventory revalued at the date of acquisition the segment also recorded million of net restructuring and other charge for severance and other cost associated with facility consolidation in the and europe the impairment of acquired technology in development and pre acquisition litigation related matter analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge including million of charge to selling general and administrative expense principally third party transaction cost related to the acquisition of gatan subsequently terminated the segment also recorded million of restructuring and other cost primarily for employee severance and other cost associated with facility consolidation in the and europe specialty diagnosticsin the specialty diagnostics segment recorded million of net restructuring and other income primarily gain on the divestiture of it anatomical pathology business see note the segment also recorded million of charge to selling general and administrative expense principally third party transaction cost in connection with the sale of the anatomical pathology business laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge the segment recorded charge to cost of revenue of million to conform the accounting policy of recently acquired business with the company accounting policy and million of charge to selling general and administrative expense principally third party transaction integration cost for recently completed acquisition the segment also recorded million of restructuring and other cost primarily charge for severance at business streamlining operation and employee compensation due at brammer bio on the date of acquisition fisher scientific inc note to consolidated financial statement continued corporatein the company recorded million of net restructuring and other cost principally for severance at it corporate operation partially offset by income from favorable result of product liability litigation the company recorded net restructuring and other cost by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts nettotallife science solution analytical specialty diagnostics laboratory product and corporate the principal component of net restructuring and other cost by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other income the segment recorded charge to cost of revenue of million for the sale of inventory revalued at the date of acquisition well million of charge to selling general and administrative expense primarily third party transaction integration cost related to recent acquisition the segment also recorded million of net restructuring and other income principally for million net gain on the resolution of litigation partially offset by charge for severance other cost associated with facility consolidation in the analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge the segment recorded net charge to cost of revenue of million for the sale of inventory revalued at the date of acquisition million of net charge to selling general and administrative expense principally third party transaction cost related to the acquisition of gatan and million of restructuring and other cost primarily for employee severance and other cost associated with facility consolidation in the and europe well abandoned facility cost associated with the remediation and closure of manufacturing facility in the specialty diagnosticsin the specialty diagnostics segment recorded million of net restructuring and other charge including million of net charge to selling general and administrative expense principally third party transaction cost in connection with the planned sale of the anatomical pathology business the segment also recorded million of net restructuring and other income including million gain on the sale of real estate mostly offset by cash charge for severance and other cost associated with facility consolidation in the and europe laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge the segment recorded charge to cost of revenue of million principally for the sale of inventory revalued at the date of acquisition and million of charge to selling general and administrative expense for third party transaction integration cost related to the acquisition of patheon the segment also recorded million of restructuring and other cost primarily charge for environmental remediation associated with superfund site in the employee severance and to lesser extent hurricane response cost corporatein the company recorded million of net restructuring and other income principally income from favorable result of product liability litigation mostly offset by charge for environmental remediation at an abandoned facility and to lesser extent severance at it corporate operation fisher scientific inc note to consolidated financial statement continued the company recorded net restructuring and other cost by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts nettotallife science solution analytical specialty laboratory product and corporate the principal component of net restructuring and other cost by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other charge the segment recorded million of charge to selling general and administrative expense principally for change in estimate of acquisition contingent consideration the segment also recorded million of restructuring and other income net including million of net credit principally for pre acquisition litigation related matter and to lesser extent net gain on the settlement of retirement plan these credit were largely offset by million of cash restructuring cost including million of severance and related cost primarily to achieve acquisition synergy and million of abandoned facility cost primarily for the consolidation of facility in the analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge the segment recorded charge to cost of revenue of million for the sale of inventory revalued at the date of acquisition well million of restructuring and other cost primarily for severance and other cost to achieve acquisition synergy well charge for the settlement of retirement plan specialty diagnosticsin the specialty diagnostics segment recorded million of net restructuring and other charge principally charge for litigation related matter and to lesser extent cash cost for employee severance and other cost associated with headcount reduction in the and europe laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge the segment recorded charge to cost of revenue of million including million to conform the accounting policy of patheon to the company accounting policy and million for sale of inventory revalued at the date of acquisition the segment also recorded million of charge to selling general and administrative expense including million for third party acquisition transaction cost well million to conform the accounting policy of patheon to the company accounting policy the segment also recorded million of restructuring and other cost primarily for employee severance and compensation due at patheon on the date of acquisition and to lesser extent hurricane response impairment charge corporatein the company recorded million of net restructuring and other income principally million of income from favorable result of product liability litigation partially offset by charge for the settlement of retirement plan and severance at it corporate operation fisher scientific inc note to consolidated financial statement continued the following table summarizes the cash component of the company restructuring plan the non cash component and other amount reported restructuring and other cost net in the accompanying statement of income have been summarized in the note to the table accrued restructuring cost are included in other accrued expense in the accompanying balance sheet in million severanceabandonment of excessfacilitiesother totalbalance at december cost incurred in reserve reversed payment currency balance at december cost incurred in reserve reversed payment currency translation balance at december cumulative effect of accounting change cost incurred in reserve reversed payment currency translation balance at december other includes relocation and moving expense associated with facility consolidation well employee retention cost which are accrued ratably over the period through which employee must work to qualify for payment represents reduction in cost of plan excludes million of net credit associated with litigation related matter and million of other restructuring charge net primarily for hurricane response impairment charge associated with the settlement curtailment of retirement plan and non cash compensation due at an acquired business excludes million of income net primarily associated with litigation related matter gain on sale of real estate charge for environmental remediation and hurricane response cost excludes million of net gain on the sale of business and million of other restructuring charge net primarily for the impairment of acquired in process research and development pre acquisition litigation related matter and compensation due to employee on the date of acquisition impact of adopting new lease accounting guidance on january the company expects to pay accrued restructuring cost primarily through fisher scientific inc note to consolidated financial statement continued note unaudited quarterly information in million except per share amount first second third fourth revenue gross net earnings per share amount reflect aggregate restructuring and other item net follows cost of million income of million cost of million cost of million in million except per share amount first second third fourth revenue gross net earnings per share amount reflect aggregate restructuring and other item net follows cost of million cost of million income of million cost of million copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next